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Background: Nut allergy diagnostics is complicated, due to asymptomatic
sensitization and pollen-induced cross-sensitization. In addition, it is usually a
life-long disease, and traditional treatment involves the avoidance of nuts and
the administration of emergency medication in accidental exposures.
Aims: To study nut allergy diagnostics by evaluating associations with nut- and
birch pollen sensitizations and the performance of IgE microarray in peanut
allergy diagnostics. In addition, to study the efficacy and safety of oral peanut
immunotherapy and how the treatment modifies antibody profiles.
Methods: We analyzed nut- and birch pollen sensitizations in a register of over
100,000 subjects from southern and northern Finland. We studied IgE
microarray and avoidance diets in 102 patients who underwent a peanut
challenge. In order to assess immunotherapy efficacy and antibody changes, we
conducted an intervention study in which 39 patients received peanuts orally
with increasing doses, and 21 patients served as controls.
Results: Nut sensitizations associated strongly with birch pollen sensitization in
both southern and northern Finland, and in this regard hazelnut, peanut, and
almond sensitizations exhibited the strongest links. Up to 84% of hazelnut-
sensitized patients had simultaneous sensitization to birch pollen, while the
majority of sensitized subjects reported no or only mild oral symptoms from
exposure to nuts. In the microarray, Ara h 2 and Ara h 6 were the most accurate
allergens in discriminating between peanut allergy and tolerance. Commonly,
peanut-sensitized patients avoided several nut species, but in the species-
specific tests, sensitization to other nuts was infrequent. In immunotherapy, 33
(85%) of 39 patients achieved the target dose of 800 mg peanut protein
(approximately four peanut kernels), and specific IgG4 increased strongly. No
neosensitizations emerged in the microarray screening, but IgE levels decreased
for the most important peanut allergens, Ara h 2 and Ara h 6.
Conclusions: The impact of birch pollen sensitization on nut sensitizations is
remarkable in Finland, and so it should be taken into account in nut allergy
diagnostics. Based on species-specific allergen tests, patients can introduce
several previously avoided nuts into their diet. Peanut oral immunotherapy is
effective in desensitizing severely allergic children and adolescents. No
neosensitizations develop and other sensitizations are unaffected, which shows
that peanut oral immunotherapy is highly allergen-specific.
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TIIVISTELMÄ
Tausta: Pähkinäallergian diagnostiikka on haastavaa oireettoman herkistymisen
ja siitepölyjen aiheuttaman ristiherkistymisen vuoksi. Pähkinäallergia on
yleensä elinikäinen, ja perinteisenä hoitona on vain pähkinöiden välttäminen ja
ensiapulääkkeet vahinkoaltistustilanteissa.
Tavoitteet: Tutkia pähkinäallergian diagnostiikkaa selvittämällä pähkinä- ja
koivuherkistymisten yhteyksiä ja IgE-mikrosirun toimivuutta
maapähkinäallergisilla potilailla sekä tutkia maapähkinäallergian
siedätyshoidon tehokkuutta ja hoidon aiheuttamia muutoksia vasta-
aineprofiileissa.
Menetelmät: Pähkinä- ja koivuherkistymisiä selvitettiin yli 100 000 potilaan
aineistossa Etelä- ja Pohjois-Suomessa. Maapähkinälle altistettujen potilaiden
(n=102) aineistossa analysoitiin IgE-mikrosiruprofiilit ja kyselytutkimuksella
arvioitiin eri pähkinälajien käyttöä. Siedätyshoitoa ja sen aiheuttamia vasta-
ainemuutoksia tutkittiin interventioasetelmassa, jossa 39 potilasta sai
maapähkinää suun kautta hitaasti nousevin annoksin ja 21 yhtä vakavasti
maapähkinäallergista potilasta toimi verrokkiryhmänä.
Tulokset: Pähkinä- ja koivuherkistymiset olivat vahvasti yhteydessä toisiinsa
sekä Etelä- että Pohjois-Suomessa. Voimakkaimmin koivuherkistymiseen olivat
yhteydessä hasselpähkinä-, maapähkinä- ja manteliherkistymiset.
Hasselpähkinäherkistyneistä jopa 84 % oli samanaikaisesti herkistynyt koivun
siitepölylle. Suurin osa pähkinäherkistyneistä ilmoitti sietävänsä pähkinöitä
täysin oireitta tai ilmoitti saavansa ainoastaan lieviä suuoireita. Mikrosiruissa
maapähkinän allergeenit Ara h 2 ja Ara h 6 erottelivat parhaiten vakavasti
allergiset. Potilaista suuri osa ilmoitti välttävänsä useita pähkinälajeja, mutta
siruanalyyseissä vain harvalla nähtiin IgE-vasteita lajikohtaisille allergeeneille.
Siedätyshoidossa tavoiteannoksen 800 mg maapähkinäproteiinia (noin neljä
maapähkinää) saavutti 33/39 (85 %) potilasta. Siedätysryhmässä spesifinen
IgG4 nousi voimakkaasti. IgE-mikrosiruprofiileissa uusia herkistymisiä ei
kehittynyt. Aikaisemmissa herkistymisissä ei tapahtunut muutoksia lukuun
ottamatta allergeeneja Ara h 2 ja Ara h 6, joiden vasta-ainetaso laski.
Johtopäätökset: Suomessa koivuherkistymisen vaikutus pähkinäherkistymiseen
on huomattava. Tämä tulee ottaa huomioon pähkinäallergian diagnostiikassa
herkistymisiä arvioitaessa. Suuri osa maapähkinäherkistyneistä potilaista välttää
useita muitakin pähkinälajeja, mutta lajikohtaisten allergeenitutkimusten
perusteella monien pähkinälajien välttö on tarpeetonta.
Maapähkinäsiedätys on tehokas hoito nostamaan oirekynnystä
maapähkinäallergisilla. Siedätys ei aiheuta uusia tai vahvista olemassa olevia




DBPCFC Double-blind placebo-controlled food challenge
FeNO Fractional exhaled nitric oxide






ISAC Immuno Solid-phase Allergen Chip
ISU-E ISAC standardized units for IgE
LOAELs Lowest observed adverse effect levels
LTP Lipid transfer protein
NOAELs No observed adverse effect levels
OAS Oral allergy syndrome
OFC Oral food challenge
OIT Oral immunotherapy
PD20FEV1 The cumulative dose of methacholine provoking a 20% decline in
forced expiratory volume in one second
PFS Pollen food syndrome
PPV Positive predictive value
PR-10 Pathogenesis-related group 10
PRACTALL Practical Allergy Report
RCT Randomized controlled trial
RR Risk ratio
SLIT Sublingual immunotherapy
SPT Skin prick test
SU Sustained unresponsiveness
TGF Transforming growth factor
TNO FARRP the Netherlands Organisation for applied scientific research Food
Allergy Research and Resource Program
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1. INTRODUCTION
Food-induced allergic reactions are an important health burden especially in
children and adolescents. Eight foods (peanut, tree nuts, egg, milk, fish,
shellfish, wheat, and soy) cause most food allergic reactions, and nuts are the
most common culprit in regard to food-induced severe allergic reactions.
Edible nuts are a heterogeneous group including species that in a botanical
sense are not what one may refer to as ‘true’ nuts. In the allergological
literature, a common classification is to separate peanut and tree nuts. Peanut,
also called a groundnut, is a legume similar to soybean and grows on the
ground. Tree nuts comprise almond, beech nut, Brazil nut, butternut, cashew,
chestnut, chinquapin, coconut, hazelnut, ginkgo nut, hickory nut, lichee nut,
macadamia nut, pecan, pine nut, pili nut, pistachio, shea nut, and walnut—
according to the U.S. Food and Drug Administration. 1
Plant-derived foods are especially interesting from an allergological point of
view, due to the phenomenon of cross-reactivity. Plant pollens as aeroallergens
can sensitize via the respiratory tract, but cross-reactive foods cause symptoms
when ingested. Some individuals experience only mild allergic reactions from
nuts, whereas others have severe and even life-threatening symptoms. It is
therefore important to separate mild allergies from severe reactions.
Unnecessary avoidance diets are a burden, but severely allergic patients still
need vigilance and the right patient advice.
In allergic sensitization, the human body produces IgE antibodies against a
normal antigen, for example food. Measuring IgE is a major part of allergy
diagnostics, but presence of IgE does not equate to a clinical allergy, as
asymptomatic sensitization is common. The food challenge is the gold standard
of food allergy diagnostics, but it poses the risk of severe reaction and is
laborious, and therefore other diagnostic methods are necessary.
In modern allergology, molecule-specific IgE, instead of the whole-allergen
specific IgE, is measured. Molecular allergology has increased diagnostic
accuracy markedly, as clinically relevant allergens instead of insignificant
cross-reacting allergens can be selected for testing.
In the treatment of food allergies, the traditional method is to avoid the
allergenic food and have emergency medications at hand in case of accidental
exposure. Immunotherapy is an established treatment in severe pollen allergy,
but immunotherapy for food allergy is currently in research. By increasing the
threshold for allergic symptoms, the allergic individual will be safe from severe
symptoms caused by accidental exposures to small amounts of the allergenic
food. By starting from very low amounts of the allergenic food, and increasing
these amounts slowly, it is possible to avoid symptoms and induce tolerance to
the allergen. A complete cure to the allergy may currently not be possible, but
symptom relief and lowering risk would be major benefits for severely allergic
11
patients and their families.
This study was undertaken to examine the diagnostics of nut allergy in an area
where birch pollen exposure is high, and to examine the efficacy and safety of




The National Institute of Allergy and Infectious Diseases defines a food allergy
as “an adverse health effect arising from a specific immune response that occurs
reproducibly on exposure to a given food.” 2 The most common childhood food
allergies are staple food allergies, caused by cow’s milk and hen’s egg. 3 These
allergies are usually outgrown, in contrast to nut and shellfish allergies, which
tend to persist into adulthood. Food allergies are classified based on underlying
immunological mechanisms. Most food allergies are IgE-mediated and result in
rapid symptoms, while non-IgE-mediated food allergies are delayed in the onset
of symptoms and significantly less common. Mixed-type (IgE- and cell-
mediated) allergies include food-allergy-associated atopic dermatitis,
eosinophilic esophagitis, and other eosinophilic gastrointestinal disorders. 4
In IgE-mediated reactions mast cells and basophils release preformed
inflammatory mediators which lead to an immediate reaction. Nut allergies are
mostly IgE-mediated.
2.2 IMMUNOLOGY OF AN IGE-MEDIATED
FOOD ALLERGY
Immunoglobulin E (IgE) was discovered in 1967. 5, 6 The overall amount of IgE
in the human body is low compared to other immunoglobulins, and it is needed
to prevent helminth infections, however, the body also produces IgE in allergic
sensitization. In addition to IgE, IgG4, which is also associated with allergies, is
a member of the IgG antibody isotype that includes four subtypes (1-4), of
which IgG1 is the most abundant. IgG4 is produced in response to chronic
allergen exposure, and it has anti-inflammatory features. Importantly, it has
been associated with tolerance to allergens. 7
2.2.1 ORAL TOLERANCE AND SENSITIZATION VIA THE
GASTROINTESTINAL TRACT
Not being allergic to a food requires an active process to take place, known as
‘oral tolerance’, 8 but when this tolerance fails, allergic sensitization takes
place. 9 Antigens transfer from the intestinal lumen via the epithelial barrier,
which after an antigen-presenting cell captures the antigen, migrates to the
lymph node, and presents the antigen to a naive T cell. In oral tolerance, the
naive T cell develops into a regulatory T cell on the basis of antigen and
cytokine signaling. Retinoic acid, indoleamine 2,3-dioxygenase, and TGF-beta
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provide critical signals for regulatory T cell development, and T regulatory cells
suppress inflammatory reactions by producing cytokines such as TGF-beta and
IL-10. When oral tolerance fails and sensitization occurs, the naive T cell
develops into a T helper type 2 cell, which acts on B cells by IL-4 and IL-13,
causing the B cells to switch from producing IgM to IgE. 10
2.2.2 SENSITIZATION VIA OTHER ROUTES
Allergens can enter the body through the airways, the gastrointestinal tract, or
the skin. Atopic children with defects in the skin barrier may become sensitized
to a food allergen without prior oral contact to the allergen. 11 The oral ingestion
of allergenic proteins is suggested to promote tolerance, whereas skin contact
leads to sensitization. Filaggrin mutation, which impairs the skin barrier, is a
risk factor in peanut sensitization, 12, 13 and recent evidence shows that early
peanut introduction promotes oral tolerance. 14
2.3 CHARACTERISTICS OF A NUT ALLERGY
2.3.1 PREVALENCE OF NUT ALLERGIES
Publications on nut allergy prevalence report sensitization to nuts, self-reported
allergies, and challenge-confirmed allergies. In a Finnish study, the prevalence
of parent-reported nut allergy was 3.1% in children starting elementary school.
15 Of Finnish students with atopy, 23% reported symptoms from tree nuts and
17% from peanut. 16
In a meta-analysis, peanut allergy prevalence in Europe was 0.4% for overall
self-reported lifetime prevalence, while skin prick test positivity was 1.7%. The
most prevalent in this regard was IgE positivity at 8.6%. The challenge-
confirmed peanut allergy accounted for 0.2%. The prevalence estimates were
higher in Western Europe compared to other regions. 17
In tree nut allergies, the overall self-reported lifetime prevalence was 1.3%, skin
prick test positivity 0.6% and challenge positivity 0.5%. Tree nut allergy
estimates were higher in Northern Europe. 17 A systematic review in 2015
reported tree nut allergy prevalence in Europe, the USA, and the UK and
included almond, Brazil nut, cashew, hazelnut, macadamia, pecan, pistachio and
walnut. Prevalence of challenge-confirmed tree nut allergy was less than 2%.
Prevalence estimates that included tree nut allergy with oral allergy syndrome
(OAS) were higher, at 8 to 11.4%, and originated mainly from Europe.
Hazelnut was the most common tree nut allergy in Europe, whereas cashew and
walnut were most common in the USA. 18
In a study of European adult population, hazelnut was the most common food
sensitization (9.3%), and it correlated with sensitization prevalence to the birch
allergens Bet v 1 and Bet v 2. 19 Allergy prevalence may differ by ethnic
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background; for instance in Australia, Asian-born children have higher rates of
peanut allergy than their Australian-born peers, 20 while in South Africa, black
children have lower peanut allergy rates compared to mixed-race children. 21
2.3.2 ALLERGY ONSET
Nut allergy usually begins at an early age. 22 In Australian studies, the
prevalence of peanut sensitization peaked at 12 months, and 90% of peanut
allergy developed by six years of age. 23, 24 In a US voluntary registry, the
median age for the first peanut reaction was 14 months, and for tree nuts it was
36 months. 25 In contrast to early-onset allergy, late-onset nut allergy can be
confused more easily with a cross-allergy to pollen.
2.3.3 SYMPTOMS
Nut allergy symptoms range from mild oral itching to anaphylaxis, which is
defined as a severe, life-threatening generalized or systemic hypersensitivity
reaction. 26 Anaphylaxis usually occurs within 2 hours of allergen exposure, 27
and in food allergies it is usually within 30 minutes. 28 The first-line rescue
medication is intramuscular adrenaline. 29
2.3.4 RISK RATES AND PROGNOSIS
Nuts are the cause of most severe and even fatal allergic reactions associated
with food, with fatalities occurring especially in adolescents and young adults.30
The annual rate of accidental peanut exposure is estimated to be 12% in
children with a peanut allergy, 31 whereas data on other nuts is scarce. General
food anaphylaxis incidence is 0.14 per 100 person-years, and it is highest in
young children. 32 The incidence of fatal food anaphylaxis is 1.81 per million
person-years in food-allergic people. 33 Peanut is commonly reported as the
most common trigger of food and nut reactions. In Sweden, peanut, cashew,
and hazelnut were the most common nut allergies leading to emergency
department visits. 34 In a study of anaphylaxes, peanut was one of the most
prevalent elicitors at all ages, and at preschool age, hazelnut and cashew also
elicited anaphylaxes. 35 A German study reported foods as causing 65% of
severe allergic reactions in children, with peanut being the most common
trigger (17%), and hazelnut was third (8%). 36 Reports of trigger foods in
emergency settings may be biased toward easily identified nut species.
A nut allergy is usually a life-long burden, though peanut allergy can be
outgrown in 20% and tree nut allergy in 10% of patients. 37 In young children,
peanut allergy resolves in up to 22%, and a small skin prick wheal and a low
IgE level predict resolution. 38 The spontaneous resolution of peanut allergy
happens mainly before six years of age, and after ten years of age, natural
resolution is infrequent. 39
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2.4 NUT ALLERGENS
Allergenic plant proteins comprise both labile and stable allergens. 40 Molecular
allergology examines sensitization to specific allergenic molecules instead of
the whole allergen source. In plant-derived foods, seed storage proteins are
stable allergens that preserve their conformation in food processing (i.e.
heating, boiling) and in gastric digestion. Sensitization to seed storage proteins
is therefore associated with severe allergic symptoms. In addition to seed
storage proteins, lipid transfer proteins (LTPs) are stable proteins and
considered to associate with severe symptoms. LTPs can act as pan-allergens,
causing cross-sensitization between many species. However, most pollen-cross-
reactive allergens are usually labile and unassociated with severe symptoms, as
food processing and gastric digestion destroy their structure.
Table 1. Classification of the most important allergen families in nuts. Data
obtained from Molecular Allergology Users Guide: Part A Molecular




- Non-specific lipid transfer
proteins (nsLTPs) (PR-14)*
Resistant to heat denaturation and gastric
digestion
Species-specific allergens, except nsLTPs, which
can act as pan-allergens
Cupins
- Legumins (11S globulins)




- PR-14 proteins (Non-
specific lipid transfer
proteins)*
PR-10 group: Sensitive to heat denaturation and
gastric digestion, wide cross-reactivity between
species
PR-14 group: Resistant to heat denaturation and
gastric digestion, can act as pan-allergens
Profilins Sensitive to heat denaturation and gastric
digestion, wide cross-reactivity between species,
common pan-allergens
Oleosins Oil body-associated proteins, clinical relevance is
uncertain










































































































































































































































































































































































































































Allergen cross-reactivity is a phenomenon in which an IgE molecule, produced
specifically against a certain allergen, binds to a similar structure on another
allergen. Cross-reactivity can exist between various allergenic proteins and
between allergen sources from differing species. In pollen-induced cross-
reactivity, pollen is the primary sensitizer and can cause cross-reactivity to
various plant-derived foods. 48, 49 Some cross-reactive species pose a similar
botanical origin. In cross-reactivity, which is caused by similar species-specific
proteins, similar botanical origin is more common than in cross-reactivity
caused by pan-allergens. Pan-allergens, such as lipid transfer proteins or
profilins, can reside in species that are botanically distant. 50 Thus, botanical
origin only partly explains allergological cross-reactivity.
2.5.1 BIRCH POLLEN SENSITIZATION
Tree pollen is the most common inhalant allergen causing cross-sensitizations
to foods. 48 Finland has a very high birch pollen count 51 and birch sensitization
is the most prevalent pollen sensitization in Finland and across Northern
Europe. 52 Birch sensitization starts to occur after infancy and the rate increases
until adulthood with young adults having the highest rates. 53 Of young adults in
Finland, 28% are sensitized to birch pollen, 54 and sensitization is directed to
the major allergen Bet v 1 in 98% cases. Bet v 2 is the second most common
allergen, but it accounts only 2% of sensitization. 55 In Swedish, Austrian, and
French populations, Bet v 1 accounts similarly for over 90% of sensitization. 55,
56
2.5.2 ALLERGENS AND ORAL ALLERGY SYNDROME
Bet v 1 is the primary sensitizing agent in birch-associated food allergies, 57 and
it drives sensitizations against other PR-10 proteins. 58 Of nuts, PR-10 proteins
are characterized in almond, hazelnut, peanut, 59 and walnut. 46 Birch pollen-
related food allergy associates with Bet v 1 sensitization. 56 In general,
sensitization to PR-10-proteins does not cause severe reactions, since labile
allergens are unable to cause a primary food allergy via the gastrointestinal
tract, as they are destroyed before entering the gut. 60 PR-proteins can cause
oral allergy syndrome (OAS) which is a mild form of food allergy and includes
itching or tingling of the mouth, lips, throat, or ears. 61 In pollen season, patients
may be more prone to experience OAS symptoms. 56, 62
2.5.3 PREVALENCE AND COMMON TRIGGER FOODS
Of birch-allergic individuals, 70% are estimated to experience symptoms from
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birch-related foods. 57, 56 Subjects are more prone to experience symptoms from
foods if they have high IgE to Bet v 1 56 or if they experience symptoms from
pollen. 63 In addition to OAS, another term, pollen food syndrome (PFS), is
used to describe the phenomenon and possible symptoms of cross-sensitization
to pollen and foods. In the UK population, the majority of patients report
experiencing the first symptoms of PFS before the age of 20 years. 64
As the allergen protein families that may cause OAS are found widely in the
plant kingdom, potential trigger foods for OAS are manifold. Reported
OAS-inducing foods include apple, carrot, hazelnut, walnut, celery, soybean,
pear, peach, nectarine, 56 kiwifruit, 65 peanut, almond, mungbean, tomato,
potato, plum, apricot, cherry, 48, 64 and jackfruit. 66 Individual fruits and
vegetables differ in their symptom potency as the allergen content depends on
the cultivar and ripeness. 67
Of the nuts, hazelnut especially causes symptoms in birch-allergic individuals.
56, 64, 68 In the UK, 25-30% of PFS patients reported hazelnut as a trigger food
for pollen-related food allergy.64 Birch-allergic Austrians reported apple (80%)
and hazelnut (59%) as the most common triggers of food allergy. 56 Moreover,
in a study of hazelnut-sensitized children, half were not clinically allergic to
hazelnut despite their sensitization, and children with OAS as their only
symptom were all sensitized to birch pollen. 69 Similarly, Belgian patients with
OAS as their only symptom were sensitized to the Bet v 1-homologue Cor a 1
in hazelnut. Adults mainly had OAS as their only symptom whereas systemic
reactions were more common in children. 70 Sensitization to stable vicilin Cor a
11 occurred in patients with severe reactions to hazelnut, but not in OAS
patients. Again, severe reactions were more common in children. 71 The
findings of these smaller studies were verified in a Europe-wide study, in which
birch-pollen-associated hazelnut sensitization predominated in adulthood, and
sensitization to stable allergens was more common in children. 72
In line with hazelnut, peanut sensitization is affected by birch pollen
sensitization. In a Swedish study, children were less likely to report symptoms
if they were simultaneously birch-sensitized, compared to children that were
only peanut-sensitized. 73 Peanut was the eleventh most common trigger of
birch-associated food allergy, with 24% reporting symptoms in the Austrian
study. Almond was reported by 32% and walnut by 41% of the responders. 56 In
the UK, cashew/pistachio caused symptoms in 10-15% and Brazil nut in 20-
25% of PFS patients. In general, nuts were the third most common trigger of
PFS. 64 The prevalence of macadamia or coconut as triggers of pollen-related
symptoms was not reported. 56, 64
2.5.4 GRASS AND WEED POLLEN SENSITIZATIONS
In addition to birch, grass pollen sensitization is common with a 17%
prevalence rate in developed countries. 74 Phl p 1, an allergen belonging to a
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protein family of expansins, is the major allergen. 75 Grass pollen allergy is not
associated with food allergen cross-sensitizations as much as birch. 76, 63 In
addition to the PR-10 proteins, profilins are another family that can cause cross-
sensitization between pollens and plant-derived foods, but it seems that profilin
sensitization rarely leads to clinical symptoms. 48, 76, 77 Furthermore, birch
pollen-sensitized patients with profilin Bet v 2 sensitization are not as prone as
Bet v 1-sensitized subjects to experiencing symptoms from foods.56
Weed pollinosis may induce pollen food syndrome, though not as frequently as
birch pollinosis. 48, 78 Mugwort (Artemisia vulgaris) causes mugwort-celery-
spice- and mugwort-mustard syndromes, and ragweed (Ambrosia artemisifolia)
has cross-reactivity with melon and banana. Several allergens, including labile
and stable proteins, can be responsible of these cross-reactivities. 78
2.5.5 OTHER CROSS-REACTIVE DETERMINANTS
Lipid transfer proteins (LTPs) are pan-allergens, and in contrast to PR-10
proteins and profilins, they are stable and can cause symptoms also in processed
foods. LTP sensitization is considered to originate from primary sensitization to
peach LTP Pru p 3, but primary sensitization to pollen allergens is also possible.
79 Sensitization to LTPs in peanut 80 and hazelnut 81 can cause severe allergy,
but in Northern and Central Europe, LTP sensitization is infrequent. 82 In
Southern Europe, LTP sensitization is more common, possibly due to
differences in pollen exposure or culinary habits. 79, 83, 72
In addition to peptides of proteins, carbohydrate structures on proteins can bind
IgE and cause cross-sensitization. The IgE binding to carbohydrates of plant
allergens is considered fairly harmless. 84, 85
2.6 POLLEN-INDEPENDENT CROSS-
REACTIVITY BETWEEN NUT SPECIES
Cross-sensitization and cross-allergy occur between nut species as well as
between nuts and other plant-derived foods, without any interference from
pollen sensitization. The underlying allergens are species-specific and can
include seed storage proteins and other stable allergens. Hazelnut, cashew,
peanut, and walnut share similar IgE binding epitopes in their vicilin allergens,
which may explain part of the cross-reactivity between these species. 86 A
Dutch study showed that in a birch-endemic region, sensitizations based on
seed storage proteins in hazelnut and peanut are mostly independent. 87 Despite
the independence of pollen sensitization, concurrent pollen sensitization may
still be present, especially in regions where pollen sensitization is very
prevalent, 88 and without molecular allergology, cross- or co-sensitization
cannot be separated.
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2.7 NUT ALLERGY DIAGNOSIS
The accurate diagnosis of a nut allergy is important, in order to keep severely
allergic patients safe by giving the right patient information and prescribing
emergency medication. Unnecessary avoidance diets are burdensome and can
lower the quality of life. 89, 90 Cross-reactivity with pollen and plant-derived
foods complicates diagnostics.
2.7.1 PATIENT HISTORY
Immediate symptoms, starting in minutes through 2 hours after exposure to the
suspected allergen, are indicative of an IgE-mediated reaction. Anaphylaxis or
other immediate multisystem symptoms raise the suspicion of an IgE-mediated
allergy. If the patient has eaten the suspected food previously without
symptoms, an allergy is less likely, albeit quantity and food processing may
affect reactivity. 91 Augmenting factors, such as physical exercise, illness,
medications, and menstruation, may lower the reaction threshold or worsen
allergy symptoms. 92 As nuts may already cause symptoms in small amounts, 93
hidden allergens are possible triggers of symptoms, and small children
especially may have no known exposure to the suspected food.
2.7.2 SKIN PRICK TESTS IN THE DIAGNOSIS OF NUT
ALLERGY
The purpose of skin prick testing is to examine sensitization to an allergen and
thereby interpret the clinical allergy. The method should always include positive
and negative controls. 94 Test extracts commonly include the whole allergen
source, i.e. a fruit, nut, pollen, or animal dander, but allergen-component-based
testing is also possible. 95 Testing with raw products, in the case of fruits,
vegetables, or nuts, is considered more sensitive than extract-based testing, as
labile allergens are preserved in the raw products. However, the allergenic
content of natural products can vary according to ripeness or the cultivar. 67
As a skin prick test (SPT) is an in vivo test, it is regarded also as a “mini-
challenge”, and it poses a possible risk of systemic allergic reaction. The
highest risk for severe reactions is considered with nuts. 96 SPT wheal size is a
continuum, and several cut-offs for clinically significant sensitization in
different allergens have been proposed. With bigger wheal sizes, a clinical
allergy is more probable. 97 Meta-analysis on skin prick test in peanut allergy
diagnosis showed 95% sensitivity, but only 61% specificity in pooled analysis
when a cut-off was set to 3mm. 98 Negative (<3 mm) skin tests have a good
negative predictive value for clinical allergy. 99, 100, 101, 102, 103 In peanut allergy,
the cut-off for a 95% positive predictive value (PPV) would be at least 7 to 8
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mm, and for a 100% PPV this would rise to 15 mm. 103 Wheals between 3 to 7
mm are somewhat of a gray area, in that an allergy or tolerance is difficult to
determine. 104  In general, in young children, the cut-off for clinical allergy can
be lower than in older children or adults. 103, 99, 104, 105 A study on peanut and
several tree nuts in children and adolescents reported that under 3 mm wheals
showed over 90% negative predictive value in most species. A high positive
predictive value was reached in most species at 6 to 8 mm wheals. 99
2.7.3 SERUM IGE TESTING IN THE DIAGNOSIS OF NUT
ALLERGIES
A common singleplex test (one assay per sample) for detecting specific IgE in
serum is based on a sandwich immunoassay, in which the allergen is
immobilized on a solid phase. IgE in the patient serum sample binds the
allergen molecule. After washing away unbound non-specific IgE,
fluorescence-labeled anti-IgE antibodies bind to the allergen-IgE-complexes
and the measured fluorescence corresponds to the quantity of specific IgE in the
sample. 42 As in the skin prick test, both whole-nut extracts as well as specific
allergen components, from either natural or recombinant origins, can be used.
In natural allergens, carbohydrate determinants may cause unspecific IgE
binding. As in the skin prick test, IgE levels are a continuum and a specific cut-
off for clinical allergy is difficult to determine. Cut-offs between 10 and 19
kU/L are proposed to predict at least 95% probability in peanut, hazelnut, and
walnut allergies. 104, 106, 105, 107
2.7.3.1 Component-specific IgE and clinically significant
levels
The use of molecular allergology has improved allergy diagnostics markedly.
The measurement of specific IgE to seed storage protein components,
especially 2S albumins, has increased both the sensitivity and the specificity of
nut allergy diagnosis to over 90 percent. The relevance of the allergen
components of several nut species has been studied in clinical settings through
challenge tests.
Peanut
Allergen components have been most extensively studied in peanut allergy. The
stable seed storage proteins Ara h 1, 2, 3, and 6 are usually responsible for
severe reactions, and sensitization simultaneously to Ara h 1 (vicilin) and Ara h
3 (glycinin), in addition to the 2S albumins, indicates more severe reactions. 95,
108 The 2S albumins Ara h 2 and Ara h 6 are the best predictors of clinical
peanut allergy. 109, 110, 111
The diagnostic accuracy of Ara h 2 has been studied in different patient
populations in Europe, Australia, US, Canada, Asia, and South Africa. 111, 112, 113
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In a review including studies running up until 2013, the sensitivity of Ara h 2
ranged between 60 and 100%, and specificity between 60 and 96%. 111 In
Finnish children and adolescents, Ara h 2 with 1.8 kU/L showed 80%
sensitivity and 95% specificity. 109 In the German pediatric population, a cut-off
of 0.35 kU/L for Ara h 2 had 86% sensitivity and 86% specificity. 114
Ara h 6 has not been studied as widely as Ara h 2. They both belong to 2S
albumins and have high sequence homology 115 as well as similarities in surface
structures. 116 In the Finnish study, Ara h 6 with a cut-off of 0.8 ISU-E showed
95% sensitivity and specificity. 109 Ara h 6 sensitization can also occur as
monosensitization in rare cases, but equally to Ara h 2, it has the potential to
induce severe reactions. 117, 118
Monosensitization to the cross-reactive PR-10 protein and Bet v 1-homologue
Ara h 8 indicates tolerance. 119 However, PR-10 proteins are suggested to cause
symptoms when large amounts of the allergen are ingested into an empty
stomach and/or physical exercise is combined with allergen exposure. 41 One
case report has been published, in which large amount of peanut ingested into
an empty stomach caused anaphylaxis in an Ara h 8-monosensitized patient. 120
The lipid transfer protein Ara h 9 is an important peanut allergen in the
Mediterranean, 80 but similar to other regions, Ara h 2 and Ara h 6 still exhibit
the best discriminative ability in Mediterranean child populations. 117, 121 As
LTP allergens reside near the peel of a fruit or nut, peeled products may lose
their allergenicity in patients that are monosensitized to Ara h 9. 122
Hazelnut
Hazelnut 2S albumin Cora 14 is responsible for clinical hazelnut allergy
similarly to peanut 2S albumins. In a Europe-wide study on self-reported
hazelnut allergy, fewer than 10% of subjects were sensitized to seed storage
proteins. Sensitization to the Bet v 1-homologue Cor a 1 dominated in most
regions, and LTP Cor a 8 sensitization was again most prevalent in the
Mediterranean. Sensitization to oleosin allergens occurred in all regions, though
its clinical relevance was stated as uncertain. 72
Seed storage proteins Cor a 9 (legumin) and Cor a 14 (2S albumin) were the
most useful allergens in Dutch children and adults. A cut-off 0.35 kU/L for Cor
a 14 showed 70% sensitivity and 76% specificity. 123 In the German child
population, Cor a 14 had the best discriminative ability with a cut-off of 0.35
kU/L yielding 85% sensitivity and 81% specificity. 114 In Mediterranean
children, Cor a 14 was the best for discriminating hazelnut allergy, with an
optimal cut-off of 0.63 kU/L, sensitivity 81.8%, and specificity 100%. 105 In




In cashew allergy, 2S albumin Ana o 3 was able to discriminate effectively
between cashew as well as pistachio allergy in Greek children. A cut-off of 0.16
kU/L yielded 98% sensitivity and 94% specificity. 125 In Dutch children, seed
storage proteins Ana o 1, 2, and 3 accurately discriminated tolerant from
allergic, but the superiority of any of the three seed storage proteins was not
reported. 126 In German children, Ana o 3 was a good predictor of a clinically
relevant allergy, and with a cut-off of 0.3 kU/L, sensitivity was 93% and
specificity 90%. 127
In discriminating pistachio allergy in Greek children, cashew Ana o 3 showed
97% sensitivity and 94% specificity when the cut-off was set to 0.16 kU/L. 125
Pistachio allergens have been studied in vitro. 2S albumin Pis v 1 was the
leading IgE reactive protein in an in vitro study. 128 Vicilin, Pis v 3, cross-reacts
with the homologous Ana o 1 from cashew. IgE reactivity to Pis v 3 was found
in patients with allergy to both pistachio and cashew, or those who were
cashew-allergic but had never eaten pistachio. 129
Walnut and pecan
Specific IgE to Jug r 1, 2S albumin in walnut, has the highest discriminative
ability in walnut allergy. LTP Jug r 3 was not a relevant allergen in Dutch and
British studies. 130, 131 Sensitization to vicilin Jug r 2 from ImmunoCAP, a
native allergen, was associated with sensitization to cross-reactive carbohydrate
determinants and did not indicate a clinical allergy. 132 In addition, Jug r 2 in the
ISAC microarray exhibited low discriminative ability. 130 Similar to peanut and
hazelnut, Jug r 1 is the most prevalent sensitization in Northern and Central
Europe and Northern America, whereas LTP Jug r 3 predominates in Southern
Europe. 133
Pecan 2S albumin Car i 1 was characterized as a major allergen in an in vitro
study, in which 79% of patients’ sera bound to Car i 1. 134 A vicilin Car i 2 and a
legumin Car i 4 also bind IgE in pecan allergic patients’ sera, but not as
commonly as 2S albumin Car i 1. 47, 135
Other nuts
Studies on almond allergy are very limited. Publications on chemical
characteristics of almond 2S albumin are somewhat controversial and its
clinical characteristics have not been studied. 136, 44, 45 Pru du 6 (11S globulin) is
a major almond allergen with up to 50% of patients’ sera binding to it in an in
vitro study. 137
Brazil nut 2S albumin has been assessed in a clinical study. Ber e 1 yielded 75%
sensitivity and 94% specificity with a cut-off of 0.25 kU/L in a study of 36
patients. 138
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Publications on the allergen-component diagnostics of coconut and macadamia
allergies are limited. Currently, a 7S globulin Coc n 2 139 and an 11S globulin
Coc n 4 are described as coconut allergens and responsible for allergic
reactions. 140, 141 In macadamia, 12 kDa, 17.4 kDa, and 45 kDa proteins have
been described as potential allergens. 142, 143
2.7.4 RATIOS OF SPECIFIC IGE TO TOTAL IGE AND
SPECIFIC IGG4 TO IGE
Previously, the ratio of specific IgE to total IgE has been suggested as being
more accurate in the diagnostics of peanut allergy than specific peanut IgE
alone. 144 However, the ratios of component-specific IgE to total IgE do not
improve peanut, hazelnut, and cashew allergy diagnostics. 145, 127 Testing of
IgG4 alone is not recommended for food allergy diagnostics. 146 However, as
IgG4 antibodies may indicate tolerance, the level of specific IgG4 compared to
specific IgE might offer greater accuracy for food allergy diagnostics.
Nonetheless, patients with high IgE may produce the highest IgG4 levels and
therefore, the IgG4-to-IgE ratio is inferior to IgE alone. 147, 148 In birch-pollen-
allergic patients, IgG4-to-IgE ratios to apple and hazelnut PR-10 allergens are
lower in those patients who experience symptoms from these foods, but as the
ratios are highly variable, they are not suitable for diagnostics of birch pollen-
related food allergy. 56
2.7.5 MICROARRAY
In addition to the singleplex assay, a multiplex microarray can be used to
measure IgE simultaneously for several allergens. The array includes
immobilized allergens that bind IgE from one sample. A commercial Immuno
Solid-phase Allergen Chip (ISAC) includes 112 predefined allergens that
originate from 51 allergen sources. Both recombinant and natural allergens are
included. The method of IgE detection is based on immunofluorescence and is
semiquantitative. 149 The detection limit is 0.3 ISU-E (ISAC standardized units
for specific IgE), which is usually also considered as a cut-off for positive.
The array comprises foods of plant and animal origins, pollens from trees and
grasses, animal dander, latex, mite, mold and insect venoms. Of the allergenic
protein families present in nuts, it includes 10 PR-10 allergens, 14 seed storage
proteins, four profilins, and nine LTPs. Of nuts and seeds, it includes six
allergens from peanut, three from hazelnut, one from sesame seed, one from
cashew, three from walnut, and one from Brazil nut. (Table 3).
An important use for an allergen microarray is to screen IgE for a large number
of possible trigger allergens in cases of unspecific anaphylaxis. 150 The array is
more expensive than singleplex tests, but when larger numbers of singleplex
tests are needed, the array is cost-effective. 151 A disadvantage of a predefined
panel is that it may provide results that are not of interest in a specific patient
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and only lead to unnecessary and costly further examinations which distress the
patient and family. 151, 152
The microarray has markedly lower amounts of allergen than singleplex tests,
which may lead to competition in antibody binding. IgG4 antibodies can act as
blocking antibodies in the IgE microarray and result in falsely low results of
IgE, if the amount of allergen binds primarily to excess IgG4. 153 In
immunotherapy, this competitive binding may be of use when increasing IgG4
leads to lower IgE results. This approach could even be beneficial in monitoring
the immunotherapy response. 154, 155
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Table 3. Allergens in the Immuno Solid-phase Allergen Chip (ISAC)
(ImmunoCAP ISAC©, Thermo Fisher Scientific, Uppsala, Sweden)
Plant foods: Grass pollen:
Kiwi (Act d 1, 2, 5, 8) Bermuda grass (Cyn d 1)
Celery (Api g 1) Timothy (Phl p 1, 2, 4, 5, 6, 7, 11, 12)
Apple (Mal d 1)
Peach (Pru p 1, 3) Weed and flower pollen:
Cashew (Ana o 2) Ambrosia (Amb a 1)
Brazil nut (Ber e 1) Mugwort (Art v 1, 3)
Hazelnut (Cor a 1.0401, 8, 9) Chenopodium album (Che a 1)
Walnut (Jug r 1, 2, 3) Mercurialis annua  (Mer a 1)
Sesame (Ses i 1) Parietaria judaica  (Par j 2)
Peanut (Ara h 1, 2, 3, 6, 8, 9) Plantago lanceolata  (Pla l 1)
Soy (Gly m 4, 5, 6) Salsola kerneri (Sal k 1)
Wheat (Tri a 14, 19.0101, aA_TI)
Buckwheat (Fag e 2)
Animal foods: Mites:
Milk (Bos d 4, 5, 8,
Bos d lactoferrin)
Dermatophagoides (Der p 1, 2, 10,
Der f 1, 2 )
Bovine serum albumin (Bos d 6) Blomia tropicalis (Blo t 5)
Ovomucoid (Gal d 1) Lepidoglyphus destructor (Lep d 2)
Ovalbumin (Gal d 2)
Conalbumin (Gal d 3) Parasites:
Egg yolk (Gal d 5) Anisakis simplex (Ani s 1, 3)
Cod (Gad c 1)
Shrimp (Pen m 1, 2, 4)
Mold: Cockroaches and insects:
Alternaria (Alt a 1, 6) Cockroach (Bla g 1, 2, 5, 7)
Aspergillus (Asp f 1, 3, 6)
Cladosporium (Cla h 8) Animals:
Tree pollen: Dog (Can f 1, 2, 3, 5)
Alder (Aln g 1) Cat ( Fel d 1, 2, 4)
Birch (Bet v 1, 2, 4) Mouse (Mus m 1)
Hazel tree (Cor a 1.0101) Horse (Equ c 1, 3)
Cypress (Cup a 1)
Japanese cedar (Cry j 1) Insect venoms:
Olive tree (Ole e 1, 7, 9) Bee venom (Api m 1, 4)
Plane tree (Pla a 1, 2, 3) Vasp venom (Pol d 5, Ves v 5)
Other:
Latex (Hev b 1, 3, 5, 6.01, 8) Bromelain-derived cross-reactive
carbohydrate chain
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Allergen families on the ISAC platform that are of special interest in nut and
birch pollen sensitizations:
Seed storage proteins:
 2S albumins: Brazil nut Ber e 1, Peanut Ara h 2 and Ara h 6, Walnut
Jug r 1, Sesame Ses i 1
 11S globulins: Cashew Ana o 2, Hazelnut Cor a 9, Peanut Ara h 3
 7S globulins: Walnut Jug r 2, Peanut Ara h 1
PR-10 proteins:
Peanut Ara h 8, Hazelnut Cor a 1.0401, Hazel tree pollen Cor a 1.0101,
Birch tree pollen Bet v 1
Lipid transfer proteins:
Hazelnut Cor a 8, Walnut Jug r 3, Peanut Ara h 9
2.7.6 FOOD CHALLENGE
The double-blind placebo-controlled food challenge is the gold standard of food
allergy diagnostics. 2 Challenge protocols vary according to the starting dose,
the time interval between doses, the number of doses, and the cumulative dose.
The American and European Practical Allergy Report (PRACTALL)
recommends conducting the double-blind placebo-controlled challenge over
two days. 156 In addition to the patient, the caregiver, the nurse, and the treating
physician should be blinded. After a blinded active challenge without
symptoms, the challenge can be continued openly with a higher dose.
Antihistamines and other medications with antihistaminic properties should be
avoided before the challenge. 156
2.7.6.1 Dosing
The cumulative allergen dose during the challenge should be at least 2g of food
protein. The PRACTALL recommends 3-10-30-100-300-1000-3000 mg doses
of protein and at least 20 min intervals between these doses. 156 Longer intervals
have been studied in peanut challenges, and up to 2-hour time intervals may
reflect better the threshold for symptoms. 157
2.7.6.2 Safety considerations
The food challenge poses a risk of severe allergic reaction, and so emergency
28
care should be available. Risk factors for anaphylaxis in children’s challenges
are older age and peanut as the challenge food. 158 According to PRACTALL, a
challenge should not be conducted if the patient is experiencing unstable or
exacerbated atopic eczema, asthma, urticaria, or allergic rhinitis. Furthermore,
if the patient has a health condition that poses special risks when treating
anaphylaxis, i.e. unstable angina pectoris, cardiac disease or dysrhythmias,
severe chronic lung disease, or pregnancy, the challenge should not be
performed. 156
2.7.6.3 Interpretation of the challenge result
The challenge should be stopped and judged as positive following the
emergence of objective symptoms. In the case of subjective symptoms, the
options are to discontinue the challenge, wait longer until the next dose, or
repeat the previous dose. If the symptoms worsen, persist for at least 45 min, or
occur repeatedly after three allergen doses, the challenge should be judged as
positive. Undertaking several challenges with both placebo and active
preparations is time-consuming, but it might be needed if the result remains
inconclusive. 156 Subjective symptoms associate with the most variability in
challenge interpretation. 159 Reactions to a placebo are possible, but in a study
of over 700 challenges, only 2.8% of placebo challenges were interpreted as
positive. Most reactions involved the worsening of atopic eczema, and these
tended to occur in young children. 160
2.7.6.4 Challenge preparation
Food matrix development requires the sufficient masking of allergenic food in
relation to taste, smell, and appearance. 161 The amount of allergenic food
should be maximized in the final preparation, in order not to result in a very
high cumulative dose. Furthermore, patients’ other allergies may limit the
possible masking ingredients. The matrix must not affect the absorption of the
allergen. High fat content may slow absorption, mask early symptoms, and
eventually lead to more severe symptoms. 162 Finally, processing may alter the
allergenicity of proteins. Roasting enhances and boiling reduces the
allergenicity of peanut seed storage proteins. 163, 164
2.7.6.5 Reaction threshold and severity
One purpose of a food challenge is to examine the eliciting dose for symptoms
in an individual patient. However, augmenting factors may alter the threshold,
and it is generally not reproducible. 165 Eliciting dose in 5% of Dutch children
was 1.6 mg protein for peanut, 0.29 mg for hazelnut, and 7.4 mg for cashew. 166
Assessment of symptoms in a quantitative scale is especially useful in research
settings. In addition to the type of symptoms and required treatment, the
severity of the reaction can be scored according to the eliciting dose. 167
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2.7.6.6 Life quality effects and reintroduction of the food
In a study of patients undergoing double-blind placebo-controlled challenges,
the health-related quality of life improved both in the challenge positives as
well as -negatives, though the improvement was greater in the challenge
negatives. 168 After a negative challenge, patients should be encouraged to
reintroduce the food into their diet. One study reported 28% of children failing
the introduction after a negative challenge. The reasons associated with failure
were experience of symptoms, aversion, fear, habit, other allergies, the patient
considering the challenge positive, and that the family was allergic to many
things in general. 169
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2.8 IMMUNOTHERAPY FOR PEANUT ALLERGY
The purpose of immunotherapy is to elevate the threshold dose for symptoms
and prevent severe reactions in accidental exposures. Desensitization is a
temporary state of unresponsiveness to an allergen and requires the continuous
consumption of the allergen. Tolerance is a permanent state of desensitization in
which even a long off-treatment period does not lead to symptoms in an
allergen exposure. 41, 170 The first published study on immunotherapy for food
allergy dates back to 1908, when a case report of egg OIT was published. 171
Since then, studies on immunotherapies to milk, egg, wheat, peanut, hazelnut,
cashew, walnut, soy, and apple have been published. Reports on
immunotherapies for nut allergies other than peanut are scarce. 172, 173 A recent
meta-analysis stated that food allergy immunotherapy may be effective in
raising the threshold of reactivity in children with IgE-mediated food allergy,
both during and post-discontinuation of the treatment. Nonetheless, the
treatment was stated to be associated with an increased risk of adverse
reactions. 174
2.8.1   STUDIES ON PEANUT IMMUNOTHERAPY
According to guidelines set out by European 9 and American allergy and
clinical immunology associations, 91 and the national Finnish working group, 3
immunotherapy for any food allergy is currently recommended for research
settings only. Most current studies on peanut immunotherapy report oral
administration of the allergen.
In 1992 subcutaneous immunotherapy for peanut allergy was reported. The
study was terminated early as a formulation error in the pharmacy caused lethal
anaphylaxis in a placebo group patient. Otherwise, the authors considered the
treatment effective and the rate of systemic reactions (13.3%) acceptable. 175 In
1997, immunotherapy with injections of aqueous peanut extract showed
efficacy, but a high rate of systemic reactions led to the conclusion that clinical
application of the treatment requires modified peanut extracts. 176 Sublingual
administration of peanut immunotherapy has been reported in several studies.
177, 178, 179, 180, 181  A US study compared oral and sublingual administration and
concluded that the safety profile is better in sublingual administration, but
efficacy is worse. 179 Epicutaneous peanut immunotherapy is currently being
studied 182, 183 and seems safe, but only modest efficacy has been reported. 182
One study reported rectal administration of recombinant peanut allergens, but it
concluded that the treatment resulted in frequent adverse events. 184 Published
studies on oral administration of peanut immunotherapy are heterogeneous
regarding protocols and primary outcomes. (Table 4) Some studies have
focused mainly on efficacy 185, 186 and some on safety. 187, 188 In addition,
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immunological changes 189, 190, 191, protocols 192, comparison of administration
routes 179, and adjuvant therapies 193, 194 have been studied.
2.8.2    THE INCLUSION OF PATIENTS
Some studies have confirmed the diagnosis of peanut allergy with either
DBPCFC or OFC, before enrolling patients on the treatment, while other
studies have included patients based on sensitization tests and patient history.
(Table 4)
Patients with severe anaphylaxis (hypotension, collapse, admission to intensive
care) have been excluded in several studies, and uncontrolled asthma, major
chronic illness, and a lack of compliance are other major exclusion criteria.
In some studies, a low threshold dose (e.g. < 100 mg peanut protein) at the
baseline challenge has been an additional inclusion criterion. 193, 195
Patients with moderate-to-severe symptoms benefit from the therapy the most,
because their risk of a severe allergic reaction is the highest. Most studies
include patients 1 to 19 years of age, with the youngest patients being 9- to 36-
month-olds. 196 (Table 4)
2.8.3 STARTING AND TARGET DOSES, BUILD-UP
SCHEDULE
The starting dose in most published studies has been 0.1 mg to 5 mg of peanut
protein. 186, 179, 197, 185 The starting dose can be the same in all patients or it can
be selected individually based on the baseline challenge threshold dose. 192
Dose increase usually takes place every one to two weeks, but it is postponed in
case of febrile illness or allergic symptoms. 198 The optimal target dose for
tolerance induction is unknown. In published study protocols, the target dose
has been 800 to 3000 mg of peanut protein. However, lower maintenance doses
(300 mg) may be equally effective in inducing immunological changes. 196
2.8.4 THE EFFICACY OF PEANUT ORAL IMMUNOTHERAPY
The efficacy of treatment can be assessed through several outcomes. One
measure of success is the ability to increase the daily dose until the target
maintenance dose is met. Peanut challenges can be conducted after the build-up
phase with a higher protein dose than the daily maintenance dose, in order to
assess desensitization to a larger amount of the allergen. Sustained
unresponsiveness is a surrogate marker for tolerance development. It is the
ability to tolerate a certain dose of peanut protein after an off-treatment period.
Sustained unresponsiveness is suggested to mimic true tolerance. In published
studies, the length of the off-treatment period has been few weeks or few
months. 199, 179, 196, 194
Maintenance dose can be achieved by 74 to 97% of patients in peanut oral
immunotherapy. 199, 186, 191, 194-197 Multiple factors affect the success rate,
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including target dose for maintenance, protocol compliance, and baseline IgE
levels. The post build-up challenge is passed by 52 to 81% of patients. 194-197, 199
The largest proportion of patients (81%) passed the end-challenge in the study,
which included the youngest children. 196 The treatment failures have been
described to have higher baseline peanut IgE levels compared to the treatment
successes. 196, 162
2.8.5 IMMUNOTHERAPY PREPARATION AND THE
ADMINISTRATION ROUTE
Most studies have used peanut flour as an OIT preparation. 200 In larger doses,
flour can be replaced by whole peanuts. The matrix for OIT preparation is
important, because taste aversion is an important issue in oral immunotherapy
to foods. 201 As food-allergic patients are commonly allergic to multiple foods,
other allergies may affect matrix design. As in the food challenge, high fat
content slows allergen absorption, which has to be taken into account in the
safety profile of the treatment and in patient advice. 162 The processing of
immunotherapy preparation affects allergenicity, and enhanced immunogenicity
and reduced allergenicity are favorable characteristics for immunotherapy
preparation. Hypoallergenic preparations, such as boiled peanut or peptides of
allergenic proteins, might be safer due to their weaker allergenicity, 164,202 but
their efficacy in inducing tolerance may be lower. Processing may also enhance
allergenicity, as roasting enhances the allergenicity of peanut seed storage
proteins, 163 and roasting and lipid binding may even stabilize labile PR-10
proteins. 203 The route of administration affects the preservation of allergens and
the efficacy of immunotherapy. Labile allergens may be destroyed in oral
administration. In sublingual immunotherapy allergens are held in the oral
cavity for 1 to 2 minutes before swallowing, and as allergens are absorbed
already in the oral cavity, peptides of labile allergens can also encounter the
local immune system. 204
2.8.6 QUALITY OF LIFE AND MOTIVATION
Food allergen immunotherapy is a laborious treatment for both the patient and
the whole family, and so quality of life has to be considered. Patients’ quality of
life has been reported to improve in peanut OIT. 186, 205 The caregiver health-
related quality of life was studied in a multi-allergen OIT, and it improved.
206,207 Life quality is associated with the safety of the treatment and it is
important to examine it in patients that discontinue the treatment due to any
reason. 208 Longer follow-up periods are necessary to assess the life quality
effects of peanut OIT. 209
2.8.7 ADVERSE EVENTS AND SAFETY
The majority of patients in peanut OIT experience adverse events. 188 Patients
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often experience mild reactions, but also severe reactions, including
anaphylaxis and near-fatal reactions occur. OIT may result in desensitization
and protection against accidental reactions, but permanent tolerance is not
usually achieved despite long-term and laborious treatment. 210 Adverse events
occur more commonly in the build-up rather than in the maintenance phase. 210,
188 Allergic rhinitis and large skin prick wheal for peanut were risk factors for
adverse events in a pooled retrospective study of 104 patients. Asthma was a
risk factor in the maintenance phase. 188 Common cofactors for adverse events
are exercise, fatigue, menstruation, the use of non-steroidal anti-inflammatory
drugs, the irregular intake of the allergen, and illness. 198 Continuous
consumption of the allergenic food may induce eosinophilic esophagitis. 211 A
meta-analysis reported a 2.7% risk of eosinophilic esophagitis after OIT, and
the disease often resolved after discontinuing OIT. 212
2.8.8 MAINTENANCE PHASE
The treatment is lifelong, and if it is discontinued, the achieved immunological
response is usually lost. 213 Compliance issues should be considered carefully
during lifelong treatment, and as the everyday dosing of the allergen for several
years is burdensome, it may be feasible to rarefy dosing. Twice per week dosing
may be equally effective in maintaining unresponsiveness. 214 Neglecting
regular dosing may lead to unexpected severe reactions. 210
2.8.9 OTHER ALLERGIES AND CROSS-PROTECTION
As many peanut-allergic patients are concurrently allergic to other nuts and/or
other food allergens, simultaneous immunotherapy for multiple allergens would
be beneficial. However, reports on immunotherapy simultaneously for multiple
foods are scarce. 215, 173 Peanut OIT does not affect tree nut or sesame IgE
levels, thus it seems that the treatment is species specific and does not offer
cross-protection. 216 In a study of birch-pollen immunotherapy, concurrent
hazelnut allergy showed no clinical improvement, albeit favorable immune
modulation took place. 217 The risk of developing new sensitizations during



















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































2.9 IMMUNOLOGICAL CHANGES DURING
IMMUNOTHERAPY
When desensitization or tolerance develops, changes take place at both the
cellular and the humoral level. Similar mechanisms are present in natural
tolerance development as well as in immunotherapy. 222
Figure 1. Oral immunotherapy and immunological changes. Adapted from
Nowak-W grzyn and Albin 170 with permission of the copyright holder © 2014
John Wiley & Sons Ltd.
Peanut immunotherapy leads to suppression of basophil activation. The
upregulation of basophil surface markers shows suppression in patients during
active OIT. 223, 190, 189
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The changes in allergen-specific IgE levels have been widely documented, 224
whereby they increase initially but decrease in the long-term. In successful
patients, IgE levels decrease more than in treatment failures. 189 Irrespective of
the change in the amount of specific IgE, the epitope repertoire of IgE broadens
during peanut immunotherapy in many patients. 224 Continuous allergen
exposure leads to an increase in the allergen-specific IgG4 level. 189 In B cell
class switch recombination, the DNA encoding for IgG4 is upstream of the
DNA encoding for IgE and is deleted during the class switch to IgE; thus, a
switch back to producing IgG4 is not possible. 225 How IgE production shifts to
IgG4 is unclear, but it probably involves anergy or the deletion of IgE-
producing B cells and an increase in IgG4-producing B cells. 226 In general, the
production of IgG4 requires frequent exposure to the allergen. IgG4 is a weak
antibody as far as activating effector cells are concerned, but it does have high
affinity and can therefore act as a blocking antibody. Both IgE and IgG4
production are induced by IL-4, but IL-10 and T regulatory cells may be crucial
in favor of IgG4. 225 IgG antibodies act through FcgammaRIIb inhibitory
receptors in suppressing IgE-mediated reactions. 227 A greater increase in IgG4
may be associated with better outcomes in immunotherapy; 190, 228 however,
epitope specificity seems important in immunotherapy-induced IgG4. 228 In
birch pollen immunotherapy, IgE and allergen-specific immunotherapy-induced
IgG4 recognize similar Bet v 1 epitopes, which in turn determines if cross-
protection occurs. 229, 173, 230 Birch pollen immunotherapy can induce Bet v 1-
specific IgG4 that cross-reacts with related food allergens and competes with
the IgE of similar epitopes. 231 In addition to changes in IgE and IgG, after
peanut OIT, levels of serum IgA increase. 227 An IgA increase has been shown
to occur also after milk 232 and egg OITs, 233 and after sublingual peanut
immunotherapy, allergen-specific IgA levels increase in the saliva. 234
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3. AIMS OF THE STUDY
The aims of this thesis are to study the following:
1) Nut allergy diagnostics by evaluating:
 nut sensitizations and their clinical relevance in a birch-endemic area
(Study I)
 IgE microarray profiles in peanut-challenged patients, and assessing
nut-avoidance diets (Study IV)
2) Peanut oral immunotherapy, by assessing:
 the efficacy and safety of peanut oral immunotherapy (Study II)
 antibody changes in IgE microarray and singleplex measurements
during immunotherapy (Study III)
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4. MATERIALS AND METHODS
4.1 PATIENTS
Several study populations were used in this thesis for assessing both nut allergy
diagnostics and oral immunotherapy for peanut allergy.
A large register-based study population was gathered in Helsinki to study nut
allergy diagnostics from the perspectives of birch pollen sensitization and cross-
reactivity. To compare two distinct geographical areas, we gathered data on a
smaller study population in northern Finland, Lapland Central Hospital.
Another facet of this thesis was an interventional study, which included a
population of children and adolescents referred to the hospital due to the
suspicion of peanut allergy. These patients underwent an oral peanut challenge,
thereby offering a perspective on the gold standard of food allergy diagnostics.
Furthermore, a subgroup of challenged patients either received oral
immunotherapy for peanut allergy or continued to avoid peanut. This subgroup
served in assessing of the safety and efficacy of immunotherapy and the
evaluation of antibody changes.
4.1.1 REGISTER STUDY AND INTERVIEWS
In order to study birch pollen sensitization and nut cross-reactivities, (Study I)
we gathered data on skin prick tests (SPTs) from the Skin and Allergy Hospital
database, which includes all SPTs conducted in the hospital, and we selected
tests from 1997 until the study initiation year of 2013. We selected all SPTs
conducted for birch pollen and formed a study population based on these
individuals. For these subjects, we searched the SPTs for any nut species and
formed a subpopulation of both birch pollen- and nut skin prick-tested
individuals. The included nut species were walnut, pecan, pistachio, cashew,
coconut, Brazil nut, macadamia, almond, hazelnut, and peanut. If an individual
was tested more than once, we included only the most recent result.
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Figure 2. Flow chart of patients in study I. Adapted from study I with
permission of the copyright holder © EAACI and John Wiley and Sons A/S.
Published by John Wiley and Sons, Ltd.
To assess age differences relating to sensitization, subjects with results available
for at least four nut species were included. This was done because subjects with
only three nut species examined were usually tested for hazelnut, almond, and
peanut as a part of the vegetable and spice test panel. The indication for testing
the vegetable and spice panel involves mainly the screening of any food
sensitization without specific suspicion of a nut allergy. In order to focus the
study on individuals with a suspected nut allergy, we focused on those that had
at least four nut species examined. For the age group analyses, we formed three
groups (under 5 years, 5-15 years, 16 years and older) to assess the





























development of sensitization during childhood and adolescence. In cross-
reactivity analyses, we included individuals who had all ten nut species
examined.
In addition to data from the Skin and Allergy Hospital, we gathered data from
northern Finland, Lapland Central Hospital (Rovaniemi). From an archive of
skin prick tests, we selected subjects who were sensitized to hazelnut, almond,
or peanut and had also been tested for birch pollen. Furthermore, we studied the
overall prevalence of birch sensitization in Lapland in a separate population of
359 subjects tested for birch pollen during 2011–2012.
We assessed the differences in birch pollination between the two study regions
based on pollen counts provided by the University of Turku, Aerobiology Unit
(Turku, Finland). Data included years 1995–2012 in Helsinki and years 2002–
2012 in Rovaniemi.
4.1.2 INTERVENTION STUDY
Nut allergy diagnostics were studied further in a smaller population of children
and adolescents referred to the Skin and Allergy Hospital pediatric department,
due to a suspicion of peanut allergy. The patients, aged 6–18 years, were
recruited between 2011 and 2013. Of the patients, 102 were double-blind
placebo-control challenged to peanut and thereby formed a group where the
characteristics of the challenges and details of other nut consumption could be
assessed (Study IV) (Figure 3). Previously, a separate study, concentrating
purely on peanut allergy component diagnostics, was published based on this
population. 109
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Figure 3. Flow chart of patients in studies II-IV. Adapted from study II with
permission of the copyright holder ©2016 Foundation Acta Pædiatrica.
Published by John Wiley & Sons Ltd.
Of the challenged 102 patients, a subgroup of 54 and an additional six non-
challenged patients participated in the study of peanut oral immunotherapy. Of
this group, 39 patients started immunotherapy and 21 continued an avoidance
diet. (Study II)
In order to study antibody changes during immunotherapy, we included
immunotherapy patients with available serum samples (n=58). (Study III)
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4.2 SKIN PRICK TESTING
Our skin prick testing method utilized raw nuts which were ground up unpeeled
and then mixed with 0.9% saline. A commercial extract (ALK-Abelló,
Hørsholm, Denmark; or Allergopharma, Reinbek, Germany) was used for birch
pollen testing. Histamine hydrochloride (10 mg/ml) and the allergen solvent
were used as positive and negative controls. The skin was pricked with a single-
headed metal lancet on the volar forearm. With nuts, a prick-to-prick method
was used. Results were read after 15 minutes. Wheal sizes of 3 mm or larger
were documented in millimeters, and wheals smaller than 3 mm were
documented as zero. The results for Lapland Central Hospital were reported as
0 through 4+ before mid-2009, and thereafter a similar method as in the Skin
and Allergy Hospital was used. We considered a wheal size of at least 3 mm or
1+ positive.
4.3 INTERVIEWS ON THE CLINICAL
SIGNIFICANCE OF SKIN PRICK POSITIVITY
We assessed the clinical significance of skin prick positivity by interviewing
sensitized patients. A survey of symptoms was performed with 1,307 subjects
sensitized to hazelnut, with 1,159 to peanut, and with 1,099 to almond. The
survey was conducted during 2006- 2014 at the Skin and Allergy Hospital
according to Haahtela et al. 97 All age subjects who had at least a 3 mm wheal
reaction for any of the three nuts (almond, hazelnut, or peanut) were eligible for
the study. The nurses interviewed the study subjects on site, using a structured
interview. Symptoms were categorized as conjunctival symptoms,
otorhinolaryngological symptoms (sneezing, rhinitis, congestion, pruritus of the
throat or ears), symptoms affecting the lower airways, skin symptoms, contact
urticaria, gastrointestinal symptoms (diarrhea or vomiting), and anaphylaxis.
Anaphylaxis was defined according to the 2006 criteria provided by Sampson et
al. 235
4.4 EVALUATION OF POTENTIAL
IMMUNOTHERAPY PATIENTS AND THE
CHALLENGE PROCEDURE WITH PEANUT
In addition to patient history, laboratory and skin prick tests (SPTs) were
conducted. The panel of IgE measurements included serum total IgE, peanut-
and hazelnut-specific IgE, and component-specific IgEs for peanut, hazelnut,
and cashew. The SPT panel included aeroallergens (birch, timothy, mugwort,
cat, dog, mite Dermatophagoides pteronyssinus, mold Cladosporium herbarum)
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and foods (egg, wheat, gliadin, cow’s milk, peanut, hazelnut, almond, cashew,
pecan, walnut, pistachio, Brazil nut, macadamia, coconut, sesame, linseed, pine
nut, poppy seed and sunflower seed). The patients and their families filled in
questionnaires on their previous usage of nut and seed species and on food-
specific quality of life.
A double-blind, placebo-controlled peanut challenge was performed on two
separate days. The challenge included four allergen doses: 5-50-200-1000 mg
of peanut protein resulting in a 1255 mg cumulative dose. The 1255 mg dose
corresponds approximately to six whole peanut kernels. The doses were
administered in 30-minute intervals. The challenge preparation was made up of
crushed unroasted peanut mixed with blueberry powder and banana chips. The
matrix served as a placebo. The challenge was considered positive only in the
case of objective symptoms.
4.5 IMMUNOTHERAPY INTERVENTION
All patients enrolled in oral immunotherapy had a moderate-to-severe reaction
at the baseline DBPCFC. Six patients in the control group were not challenged
but had high Ara h 2 (range 27.8 to 365 kU/L). Patients who had poor asthma
control (forced expiratory volume in one second, FEV1 <80%), any major
chronic illness, or ongoing immunotherapy were excluded. The OIT group
underwent the eight-month OIT build-up phase, in which the amount of peanut
protein increased from 0.1 mg to 800 mg (approximately four whole peanuts)
per day. As an OIT preparation, roasted defatted peanut flour (50% protein,
12% fat Byrd Mill, VA) was used mixed with soy- and milk-free margarine
(Keiju 70%, Raisio, Finland). From week 20, patients used whole peanuts,
which could be raw or roasted according to patients’ preferences. Patients took
antihistamines daily during the build-up phase. Adverse symptoms were
assessed on scheduled hospital visits and with additional phone calls and check-
ups, when needed. The patients were provided with an adrenalin autoinjector,
antihistamines, and prednisolone in the case of adverse reactions.
After reaching the maintenance dose of 800 mg peanut protein, the DBPCFC
was repeated. Desensitization was defined as the ability to pass the DBPCFC
with 1255 mg peanut protein. In the control group, failure to desensitize was
confirmed by the peanut challenge, or persistent high serum IgE to Ara h 2. We
calculated the amount of peanut protein ingested during OIT, using the dose
increment protocol and the individual treatment days.
During the maintenance phase, the patients took four peanuts daily or three to
four times per week.
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4.6 IGE MEASUREMENTS
Serum IgE measurements in this thesis were conducted both with singleplex
ImmunoCAP assays and multiplex ImmunoCAP ISAC microarrays (Thermo
Fisher Scientific, Uppsala, Sweden). Sensitization was defined as  0.35 kU/L
in IgE ImmunoCAP and  0.3 ISU-E in ISAC. The detection limits were 0.1
kU/L for IgE in ImmunoCAP and 0.3 ISU-E in ISAC. Serum IgG4 was
measured only with singleplex ImmunoCAP assays with 0.07 mg/L as detection
limit.
IgE measurements were conducted in all patients who participated in the
intervention study. We measured serum total IgE, and specific IgE and specific
IgG4 antibodies to peanut and Ara h 1, 2, 3, 8, and 9, and hazelnut Cor a 14 and
cashew Ana o 3 using a singleplex immunoassay. In immunotherapy patients,
the IgE levels were measured in the beginning of the treatment, after reaching
the maintenance phase and after receiving one year maintenance treatment.
(Study II)
IgE and IgG4 antibodies to Ara h 6 were measured with an experimental
ImmunoCAP test in Thermo Fisher Scientific, Uppsala, Sweden. We analyzed
the ratio of IgE and IgG4 to peanut allergen components and their changes
during the immunotherapy. (Study III)
In all of the 102 challenged patients, we analyzed the general IgE sensitization
profiles on ISAC microarrays and assessed the importance of all 112 allergens
included in the array in predicting the challenge result. Furthermore, we
assessed family-reported avoidance of nut species and compared this
information to sensitizations examined with skin prick tests and sensitizations
to species-specific allergens present in the microarray. Species-specific
measurements in the ISAC microarray and in singleplex ImmunoCAPs
included peanut, hazelnut, cashew, pistachio, Brazil nut, pecan, walnut and
sesame seed. (Study IV)
4.7 AIRWAY MEASUREMENTS
As part of the immunotherapy study, we measured airway effects. A
methacholine challenge test was performed before and after the build-up phase
in the immunotherapy patients, in order to measure bronchial
hyperresponsiveness. The provocative dose causing a 20% decrease in forced
expiratory volume in one second (PD20FEV1) was measured. In addition, the
fractional concentration of exhaled nitric oxide (FeNO) was measured, utilizing
an online method using an Ecomedics CLD 88 analyzer. 236 (Study II)
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4.8 STATISTICAL ANALYSES
         4.8.1       REGISTER STUDY
The sample size in the register study (Study I) was based on available skin
prick tests in the two hospitals during the study years and the available results
from the symptom interviews. We analyzed the data with chi-square and
Fisher's exact tests for dichotomous variables. A Spearman’s rank-order
correlation was used for continuous and categorical variables. Hierarchical
clustering with Euclidean distance and the method of average linkage were used
to create an analysis of the cross-reactivities of all ten nut species. Trends in
sensitization according to age group were analyzed with the linear-by-linear
association test and a Poisson regression. All tests were done two-sided, and the
P value <0.05 was considered significant. Statistician, PhD Hannu Kautiainen
analyzed the proportion of symptomatic patients with binomial logistic
regression.
       4.8.2 INTERVENTION STUDY
The sample size of 102 patients, who were double-blind placebo-control
challenged to peanut, was based on a previous study on peanut allergy
diagnostics. They were a consecutive sample of referred patients. 109 (Study IV)
We used a Mann-Whitney-U test to compare individual allergens in
ImmunoCAP ISAC and singleplex ImmunoCAPs. In multiple pairwise
comparisons, a P value of <0.0004 was considered significant, based on the
Bonferroni method, as the comparisons included two allergens from
ImmunoCAP measurements and 112 from ImmunoCAP ISAC, i.e. totaling 114
pairwise comparisons. In other analyses, a P value <0.05 was considered
significant.
The correlation of the IgE level, the challenge threshold dose, and skin prick
wheal size was analyzed with a Spearman’s correlation, while dichotomous
variables were analyzed with Fisher's exact test. Statistician Patrik Dykiel, from
Thermo Fisher Scientific, conducted a random-forest analysis of the importance
of microarrayed allergens on predicting the challenge result.
PhDs Joost Westerhout, Marty Blom, and Ben Remington from the Netherlands
research organization TNO FARRP, analyzed the threshold doses of positive
challenges. For the threshold distribution curve, individual discrete and
cumulative no observed adverse effect levels (NOAELs), and lowest observed
adverse effect levels (LOAELs), were established in all challenge-positive
patients. The discrete and cumulative individual NOAELs and LOAELs were
analyzed through interval-censoring survival analysis and fitted to population
threshold distribution curves from which the eliciting doses could be
determined, and those predicted to provoke reactions in 5%, 10%, and 50% of
the population were estimated using the Log-Normal, Log-Logistic, and
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Weibull parametric models. 93
In the immunotherapy study (Studies II and III), the main outcome measure
was the number of desensitized patients in each group. Desensitization was
defined as the ability to pass the DBPCFC with 1255 mg peanut protein, after
the build-up phase. We calculated that the sample of 39 patients in the OIT
group and 21 in the avoidance group would provide 93% power to detect a
significant difference in the rate of desensitization between the study groups at
a 5% two-sided significance level, when assuming that 20% of the avoidance
patients would recover spontaneously and 60% of the OIT group would become
desensitized by the treatment protocol.
Prof. Dario Greco, from Helsinki University, Institute of Biotechnology,
conducted the statistical analysis of ISAC microarrays and IgG4-to-IgE ratios.
We filtered the results of the ISAC microarray so that the measured value of an
allergen had to be at least 0.3 in at least 20 OIT patients and in ten avoidance
patients (50% +1), in at least one of the four groups (OIT group pre, OIT group
post, avoidance group pre, avoidance group post), in order for the allergen to be
included in the analysis. A linear model was fitted to examine the effects of the
treatment, response, subject, gender, age, and season. Furthermore, we used
eBayes for pairwise comparisons of interest. P values were corrected using the
Benjamini-procedure. For the IgG4-to-IgE ratios, we converted IgE to mg/L
with a conversion factor of 1 kU/L = 0.0024 mg/L. R software with the limma
package was used to analyze the microarray and IgG4-to-IgE ratio results. For
other analyses, we used Fisher’s exact test and the Mann-Whitney U test to
compare two groups, while the Wilcoxon signed rank test was employed to
compare repeated measurements.
In all studies, we used IBM SPSS Statistics software (IBM, Armonk, NY,
USA), and in studies I, III, and IV we also used R program 3.0.2 (R Project for
Statistical Computing, http://www.r-project.org/).
4.9 ETHICS
The ethics committee at Helsinki University Hospital and Lapland Central
Hospital approved the studies. In addition, the study was registered at
Clinicaltrials.gov (NCT01502878). Each patient and either one of her/his




5.1 NUT ALLERGY DIAGNOSTICS IN A BIRCH-
ENDEMIC AREA
5.1.1 SKIN PRICK TESTS AND CROSS-REACTIVITIES
During the years 1997-2013, a total of 114,572 individuals were tested for birch
pollen. Baseline characteristics of the study population are presented in Table 5,
below.
Table 5. Baseline characteristics of the 114,572 individuals skin prick tested
for birch pollen. (Study I)
Age, median (interquartile range) 28 years (11-45)
Positive skin prick test for birch
pollen, n (%)
35 976 (31.4% [95% CI, 31.1-31.7%])
Tested for at least one nut species,
n (%)
50 604 (44.1% [95% CI, 43.9 - 44.5%])
CI; confidence interval
Sensitization to nut species was more common in subjects who were
simultaneously sensitized to birch pollen (P < 0.001 difference for all nut
species). Hazelnut had a 15.9-fold prevalence in birch-positives compared to
-negatives. Of hazelnut-sensitized subjects, up to 84% were concurrently
sensitized to birch pollen. (Study I, Figure 2.)
The correlation with birch wheal size was strongest with hazelnut
(Spearman  = 0.84, P < 0.001), almond (  = 0.74; P < 0.001), and peanut
(  = 0.61, P < 0.001) wheals.
In the symptom surveys, the proportion of symptomatic patients was higher in
line with increasing skin prick wheal size. (Study I, Figure 4.)
The majority of patients experiencing symptoms from nuts (57 to 66%)
reported having only otorhinolaryngological symptoms. The details of the
symptoms are shown in Table 6.
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Table 6. Details of symptoms reported by nut-sensitized subjects.








congestion, pruritus of the throat or ears) 601 (52) 766 (59) 499 (45)
Otorhinolaryngological only 421 (36) 518 (40) 378 (34)
Lung (cough, mucus, wheeze, dyspnea) 170 (15) 231 (18) 105 (10)
Skin (eczema, urticaria) 102 (9) 114 (9) 68 (6)
Gastrointestinal (vomiting, diarrhea) 51 (4) 24 (2) 12 (1)
Eyes (watering, pruritus, oedema) 29 (3) 27 (2) 14 (1)
Contact urticaria 17 (1) 27 (2) 15 (1)
Anaphylaxis 19 (2) 8 (1) 2 (0.2)
The hierarchical cluster analysis of nut species and birch pollen showed that
birch formed a cluster with hazelnut, almond, and peanut. Cashew and pistachio
formed a pair as well as pecan and walnut. (Study I, Figure 5.)
Sensitization prevalence for all nut species decreased with age in children and
young adults in those subjects that were not sensitized to birch pollen, whereas
in the birch-positives, nut sensitization prevalences seemed to increase in
adolescence. (Study I, Figure 6.)
When comparing the two geographical areas, the prevalence of birch pollen
sensitization among all the tested subjects was lower in Helsinki than in
Lapland (24.0% [95% CI, 19.6–28.4%] vs 31.4% [95% CI, 31.1–31.7%],
P = 0.003). In the nut-sensitized populations, no difference in birch sensitization
prevalence was detected in the two areas.
5.1.2 IGE MICROARRAY PROFILES AND AVOIDANCE
DIETS
Analysis of the IgE microarray profiles in peanut-challenged patients showed
that the most important allergens for predicting peanut challenge result were
Ara h 2 and Ara h 6. (Study IV, Figure S3.)
The cumulative threshold dose for the positive challenge reaction correlated
(Spearman’s rho) with the IgE levels to Ara h 1 (-0.49), 2 (-0.51), 3 (-0.54), and
6 (-0.55), but not with Ara h 8 and 9.
PR-10 sensitization was common (90% for Bet v 1) throughout the whole
group, but it did not differ between the challenge positives and negatives.
(Study IV, Figure 2.)
The avoidance habits of peanut-sensitized children and adolescents showed that
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up to 52-96% avoided some tree nut species, and only 27-44% were sensitized
to the respective species-specific proteins in the microarray.
(Study IV, Figure 3.)
5.2 ORAL IMMUNOTHERAPY TO PEANUT
5.2.1 EFFICACY AND SAFETY
Peanut OIT resulted in desensitization in 33/39 patients in the treatment group,
and 26/39 were able to tolerate 1255 mg peanut protein in the re-DBPCFC after
reaching the maintenance dose. Of the 39 patients, 31 were able to undergo the
re-DBPCFC according to the study protocol.
The tolerated peanut protein dose increased from a median 5 mg (range 0–255
mg) to 1255 mg (255–1255 mg) (P < 0.001).
The median serum IgE for whole peanut extract, and Ara h 1, 2, 3, 8, and 9
remained at the same level before and after the OIT build-up phase, whereas
serum IgG4 concentrations for the whole peanut extract, and Ara h 1, 2, 3, 6
and 8 increased significantly. (Study II, Table S2.) After one year of
maintenance treatment, the serum IgE levels for Ara h 1, 2, 3, 8, and 9
decreased in the 29/39 patients that continued the treatment.
(Study II, Table S2.)
Of the OIT patients, 33/39 had available results for the methacholine challenge
test. Forced expiratory volume in one second (FEV1) as a percentage of
predicted was unaffected during the OIT build-up phase (P = 0.14). The number
of patients with moderate or severe hyperresponsiveness, i.e. a cumulative
methacholine dose inducing a 20% reduction in FEV1 under 600 μg
(PD20FEV1 < 600 μg), did not change. However, an increase in the
methacholine dose (PD20FEV1), from 810 μg to 1451 μg, was observed
(P = 0.27). Fractional exhaled nitric oxide (FeNO) showed no change, though
the number of patients with an increased FeNO level (z-score >1.96 or
> 25 ppb) decreased from 22 to 14 patients (P = 0.08). (Study II, Table 3.)
Of the OIT patients, 30/39 (77%) reported adverse symptoms during the build-
up phase, with the majority being mild oral symptoms that needed no
medication. Five patients sought emergency medical care because of symptoms
related to the treatment, and one of these five used an adrenaline auto-injector.
In the long term, which included a median 31 months (range 1.6-52) of
treatment in the build-up and maintenance phases, an additional six OIT
patients sought medical treatment and three patients needed adrenalin for a
peanut reaction.
Food allergy-related quality of life improved from median 57 (range 1–109) to
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40 (15–101) points (P = 0.03) in the 27 patients who had available results from
the questionnaire. The 26 studied parents showed no change in their quality of
life.
5.2.2 ANTIBODY CHANGES
Changes in IgE levels in microarrays before and after OIT build-up phase
occurred only in Ara h 2 and Ara h 6. IgE for Ara h 2 decreased significantly
from a median 39 ISU-E (range 1.0–176) to 6 ISU-E (1.2–86), and for Ara h 6
from 35 ISU-E (1.4–157) to 4.9 ISU-E (1.0–37) (P < 0.0001).
(Study III, Figure 1.)
IgG4-to-IgE ratios for Ara h 1, 2, 3, 6, and the whole peanut extract increased
significantly during treatment, whereas ratios for Ara h 8 and Ara h 9 remained
stable. (Study III, Figure 2.)
The increase in IgG4-to-IgE ratios for Ara h 2, 3, 6, and the whole peanut
extract were associated with the cumulative amount of peanut protein ingested
during treatment: Ara h 2 (Spearman  = 0.50, P = 0.001), Ara h 6 (  = 0.36,
P = 0.026) (n = 38), Ara h 3 (  = 0.43, P = 0.007), and whole peanut extract
(  = 0.47, P = 0.002).
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6. DISCUSSION
This thesis includes studies on sensitization, cross-reactivities, and laboratory
diagnostics of nut allergies. We have studied oral immunotherapy for peanut
allergy and its effects on underlying sensitizations and antibody profiles.
Furthermore, we assessed avoidance of nut species in peanut-sensitized patients
and compared their avoidance diets to species-specific sensitization profiles.
6.1  METHODOLOGICAL CONSIDERATIONS
6.1.1 STUDY POPULATIONS
In the cross-sensitization study we included all patients that were skin prick
tested for birch pollen at the Skin and Allergy Hospital during the chosen study
years 1997-2013. This resulted in a very large sample size, at over 100,000
individuals. The tested individuals had all had some clinical indication for skin
prick testing, i.e. suspicion of an allergy or atopy. This makes our results
generalizable to patients that need assessment of sensitizations and advice on
the very common finding of nut sensitization. The findings of our study will
help to assess sensitized patients in primary as well as in specialist care centers.
Our study population in Rovaniemi was markedly smaller than the Helsinki
population, because the general population of Lapland is smaller and, in
addition, we were not able to include all patients skin prick tested to birch
pollen during the study years, because the archive had to be searched and saved
manually. The Rovaniemi study population of nut-sensitized patients included
mainly hazelnut-, almond-, and peanut-tested patients. Other species were very
infrequently tested, which limited the geographical comparison to only these
commonly tested nuts. We assessed overall birch pollen sensitization rates in
Rovaniemi from a separately collected population of patients that were tested
during the time when the results were reported in millimeters. For nut
sensitization, we also included qualitative results, which limited us to studying
sensitization only from a qualitative point of view.
Our study is limited by the fact that we assessed sensitizations only. Clinical
relevance was assessed only in a subgroup of patients and was based on patient-
reported symptoms and no challenges were conducted. Some patients may
possibly have experienced more severe symptoms when challenged to high
doses of nut protein, however, any severe reactions were not confirmed by the
challenge, either. Furthermore, our study population included subjects with the
clinical suspicion of birch and nut allergies, and our data are thus subject to
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overestimation of these co-sensitizations. Moreover, the findings of age-related
changes can be regarded only as indicative and may be skewed by any possible
differences in patient selection or changes in population rather than at an
individual level. Our research extends to the year 1997 and was designed to
study cross-sensitizations in skin prick tests. We were limited to skin prick tests,
and the lack of serum samples, and due to the large sample size we, we were
not able to analyze serum-specific IgE. In clinical use, however, component-
resolved diagnostics is adapted to discriminate between cross-sensitization and
true allergy.
In addition to skin prick testing, we studied the diagnostics of nut allergy in
patients who were double-blind placebo-controlled challenged to peanut. This
enabled us to compare laboratory measurement diagnostics to the gold standard
double-blind placebo-controlled challenge. Our population was selected based
on sensitization to peanut either in skin prick tests or in an in vitro IgE test for
the whole peanut extract. This makes our results generalizable to patients
referred to specialist centers or examined in a primary health care setting and
who are peanut-sensitized. Our patients had either experienced symptoms from
peanut previously or had never ingested peanut and were unaware of their
allergy status. This setting reflects true nut allergy diagnostic dilemmas
accurately, as many children, especially younger ones, have never ingested
specific nut species.
Peanut oral immunotherapy was studied in severely allergic patients. The
allergy was diagnosed with a double-blind placebo-controlled peanut challenge,
and our inclusion criteria for OIT required patients to have at least a moderate-
to-severe reaction in the challenge, in order to be eligible for immunotherapy.
Thus, our patients had a true and severe peanut allergy, and patients with only
pollen-cross-reactive peanut sensitization were excluded. This study was
designed to assess the efficacy and safety of peanut oral immunotherapy in
moderate-to-severely allergic children with even anaphylaxis, as they would
benefit the most from this treatment.
A major limitation of our study was that the study groups were not randomized
but families chose themselves whether or not they wanted to have
immunotherapy. Also, subgroup analyses according to outcomes were limited in
this study, because the study was powered to show the efficacy of
desensitization. Thus, we were unable to unravel factors that would predict
success in OIT.
In the study of antibody changes during immunotherapy, we included all
patients that received the intervention and control patients that continued to
avoid peanut, i.e. the traditional treatment for nut allergy. Two patients from the
avoidance group were excluded because of an unavailable serum sample.
The sample size in peanut oral immunotherapy was based on the primary
outcome, which was the ability to pass the end-challenge after achieving the
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maintenance phase. Thus, we were limited to this sample size when assessing
our secondary outcomes.
6.1.2 CHALLENGES
Peanut challenges were conducted in a double-blind placebo-controlled fashion,
which is the gold standard of food allergy diagnostics. The cumulative 1255 mg
protein dose is sufficient to exclude reactivity to accidental amounts of peanut.
The study challenges were conducted according to PRACTALL guidelines, 156
which makes them generalizable to other study centers. The lowest dose of
peanut protein in our challenge protocol was selected based on clinical demands
and was set to 5 mg. Lower starting doses would have enabled us to examine
the threshold dose for the Finnish population more accurately, however, our
threshold results were in line with published thresholds from other populations.
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6.1.3 IGE MEASUREMENTS
IgE was measured both in singleplex ImmunoCAP and in multiplex microarray
ImmunoCAP ISAC. In singleplex measurements, serum samples were diluted if
the results exceeded the 100 kU/L limit, in order to measure even the highest
IgE levels in our patients, some of whom had IgE levels counting several
hundreds. We were able to study IgG4 in ImmunoCAPs as well, and this
method was not a routine standard at the time of the study.
In the IgE microarray ImmunoCAP ISAC, we were able to screen our patients
in relation to 112 allergens from a large variety of allergenic sources and protein
families. As the microarray is semi-quantitative, we were unable to compare our
results directly from the singleplex ImmunoCAPs to the microarray.
6.1.4 AIRWAY MEASUREMENTS
Airway inflammation in patients receiving peanut oral immunotherapy was
measured by examining fractional exhaled nitric oxide and airway
hyperresponsiveness by methacholine challenges. The measurements were
conducted before treatment and approximately one month after achieving the
maintenance phase, i.e. after the build-up phase. Fractional exhaled nitric oxide
is recommended for monitoring airway inflammation in patients with asthma
237, while the methacholine challenge is recommended for testing airway
hyperresponsiveness. 238 In our study, patients' asthma treatment was conducted
according to clinical needs. As asthma is a risk factor for severe reactions in
food-allergic reactions, we assessed possible asthma symptoms in all study
visits. None of our patients was excluded from the study due to poor asthma
control.
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6.2  DISCUSSION OF THE MAIN RESULTS
6.2.1 NUT ALLERGY DIAGNOSTICS IN A BIRCH-ENDEMIC
AREA–SKIN PRICK TESTING, IGE MICROARRAY
PROFILES, AND AVOIDANCE DIETS
6.2.1.1 Sensitization to nuts in a birch-endemic area,
symptoms, and cross-reactivities
The prevalence of nut sensitization was up to 84% in birch-sensitized
individuals. With higher levels of birch sensitization, an increasing proportion
of tested subjects were sensitive to multiple nuts.
Hazelnut is one of the most common food ingredients from which birch-allergic
individuals report experiencing symptoms. 56 In the Finnish population, birch
sensitization is directed mainly toward the pathogenesis-related 10 (PR-10)
protein Bet v 1 55, which in turn drives other sensitizations toward PR-10
proteins in other species. 58  Among nut species, PR-10 proteins are
characterized in hazelnut, almond, peanut 59, and walnut. 46 Our study results
showed that hazelnut, almond, and peanut cross-reacted with birch pollen the
most.
In the symptom survey, most subjects reported experiencing either no or only
mild symptoms, which were mainly otorhinolaryngological, i.e. corresponding
to oral allergy syndrome. Previous clinical studies on allergenic components in
nuts show that sensitization solely to PR-10 proteins Cor a 1 in hazelnut and
Ara h 8 in peanut causes mild or no symptoms 119, 70, whereas sensitization to
seed storage proteins Cor a 9 and 14 and Ara h 2 and 6 causes severe
symptoms. 123, 111 The mild symptom profile of our study subjects links to the
fact that nut sensitization in birch-endemic areas is mostly pollen-related and
without severe symptoms.
Age group analyses showed that young children that were not sensitized to
birch pollen were already sensitized to nuts, which is in accordance with the
allergic march, in that sensitization to foods emerges earlier than pollen
sensitization. 239 In our study, this non-birch-induced sensitization to nuts
decreased with age. The phenomenon of decreasing nut sensitization during the
first years of life was also demonstrated in the study by Peters et al., which
showed that 22% of children lost their peanut allergy by 4 years of age and
decreasing skin prick wheal size predicted the development of tolerance. 38 Our
study subjects that were sensitized to birch, however, exhibited no decrease in
sensitization to most nut species during childhood and adolescence. We
hypothesize that this is due to the increase in their pollen sensitization and their
subsequent cross-sensitization to nuts. Cohort studies on peanut allergy show
that asymptomatic sensitization increases until adulthood, but clinical reactivity
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increases only during early childhood. 240, 241 Correspondingly, this suggests that
asymptomatic peanut sensitization is induced by pollen sensitization. A Europe-
wide study showed that pollen-related allergy to hazelnut was more common in
adults than in children. 72
In our co-sensitization analyses, pecan and walnut, as well as cashew and
pistachio were the two nut pairs that showed the highest co-sensitization. These
species originate from the same botanical families, i.e. pecan and walnut from
the family Juglandaceae, and cashew and pistachio from Anacardiaceae. 242
Previous studies on skin prick tests and specific IgE show similar findings in
relation to these nut species. 243, 106, 244 In the hierarchical cluster analysis, a
similar result to the correlation analyses was present, in that almond, hazelnut,
and peanut grouped with birch pollen.
We were able to study cross-sensitizations in two distinct areas of Finland. The
distribution of birch pollen differs in the southern and the northern regions of
the country, which enabled us to compare sensitizations in areas with differing
pollen exposures. In the overall population tested for birch pollen, sensitization
was less common in the north, in accordance with the lower exposure. The very
high birch pollen count in southern Finland is markedly higher than in most of
Europe and in the USA, 245, 246 while the Rovaniemi region has birch pollen
counts comparable to central Europe.
In the comparison of nut cross-sensitizations, we selected subjects that were
skin prick tested for hazelnut, almond, and/or peanut, were sensitized to at least
one of these nuts, and had also been tested for birch pollen. In these nut-
sensitized subjects from the two regions, concurrent sensitization to birch
pollen was equally common. The comparison was limited to hazelnut, almond,
and peanut, because these were the most commonly tested nuts and offered an
adequate sample size for the comparison. The proportions were highly similar
in the two regions, when we compared the rate of hazelnut-sensitized or peanut-
sensitized subjects with simultaneously birch-sensitized subjects. Almond
showed higher concurrent birch-sensitization prevalence in Helsinki than in
Rovaniemi, though this difference failed to reach statistical significance.
Hazelnut sensitization was again associated most strongly with birch
sensitization.
Previous studies based in molecular allergology showed that peanut and
hazelnut allergies have a stronger association with birch pollen sensitization in
Northern Europe than in Southern Europe or the USA. 72, 247, 82 As Rovaniemi
has birch pollen counts similar to central Europe, our results are generalizable
outside Finland.
Our study showed that subjects with larger skin prick wheal sizes for birch
pollen had concurrent sensitization for increasing numbers of nut species. This
may reflect a general pattern where patients with stronger reactivity to one
allergen react to several allergens in general. On the other hand, this strengthens
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the finding that birch pollen sensitization is associated strongly with many nut
sensitizations.
6.2.1.2 Microarray in the diagnostics of peanut allergy, and an
assessment of the avoidance diets of nut-allergic
patients
Overall, the sensitization patterns of peanut-challenged patients showed that
peanut-allergic and -tolerant patients had a similarly high prevalence of
sensitization to PR-10 allergens. Ara h 8 sensitization was very common in our
patients, both in peanut-tolerant as well as in -allergic patients. Our finding
highlights the fact that Ara h 8 sensitization is pollen cross-reactivity and true
peanut allergy is not caused by Ara h 8 sensitization. It is not recommended to
test Ara h 8, as it seems not to add any value in differentiating severely allergic
from tolerant. 248 In line with Ara h 8, the other PR-10 protein sensitizations
were similar in the challenge-negative and -positive groups. IgE levels for the
PR-10 proteins were slightly higher in the challenge negatives, but this
difference failed to reach statistical significance. Strongly PR-10-sensitized
patients may be more likely to have been selected for our study population, as
they were more probably previously suspected of having true peanut allergy. In
addition, mild oral allergy symptoms, due to PR-10 sensitization, may have
occurred in these patients and further enhanced the suspicion of true peanut
allergy. Thus, in these patients, a controlled challenge for peanut is especially
useful in preventing unnecessary avoidance of the nut.
The threshold distribution curve of our 69 challenge positive patients showed
that our study population was representative of the generic allergic population.
When comparing the curves to a larger, previously published multinational
allergen threshold database, no significant population differences were
observed. 249 However, the starting dose in our challenge protocol was 5 mg,
and this dose leads to response in 15-20% of patients, so it was not possible to
extrapolate the eliciting doses for 5% and 10%. The calculated values for a 50%
eliciting dose were comparable to the values established by Taylor et al. 249 For
clinical purposes, a starting dose of 5 mg peanut protein is beneficial, as a
higher starting dose makes it possible to conduct the challenge in one day.
Challenge positives had higher IgE to peanut seed storage proteins, especially
Ara h 2 and Ara h 6. IgE levels to the seed storage proteins Ara h 1, 2, 3, and 6
were associated with the challenge threshold doses. Previously, a Danish study
showed a weak correlation of Ara h 1, 2, and 3 with the peanut threshold dose.
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Our highly birch-sensitized study population had skin prick positivity to several
nut species, and they also reported never having ingested many of the inquired
nuts. Coconut, almond, and sesame seed showed lower rates of avoidance,
which might be due to an overall higher consumption of these species. Coconut,
almond, and sesame are sometimes not considered nuts in a culinary sense, and
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a family may consider these species safe to eat despite setting out to avoid all
nuts. Coconut has minor cross-reactivity with other nuts and is also botanically
distant from the other species. 251, 252 As sesame seeds are used in many
convenience food hamburgers as well as Middle-Eastern and Oriental foods that
have become more popular during recent years, their consumption may have
increased. The avoidance of Brazil nut and macadamia may be affected by the
generally low supply of these species, and families may not identify these
species.
An important reason for avoiding all nuts may be that families are afraid of
cross-contamination. 253 Identifying different nut species is also difficult 254, but
unnecessary avoidance may even prevent the development of natural oral
tolerance. 14
In IgE measurements of the available seed storage proteins of nuts, we found
that sensitization to these proteins was infrequent. Concurrently, sensitization to
the whole nut species in skin prick tests was common. The high rate of
sensitization in skin prick tests is probably caused by birch cross-reactivity and
in most cases does not include sensitization to stable allergens.
6.2.2 ORAL IMMUNOTHERAPY TO PEANUT–EFFICACY,
SAFETY, AND ANTIBODY CHANGES
6.2.2.1 The efficacy and safety of peanut OIT
In peanut oral immunotherapy, 67% of the patients were desensitized, i.e. they
could tolerate 1255 mg cumulative dose of peanut protein at the end-challenge.
A larger proportion, 87%, was able to achieve the daily maintenance dose of
800 mg of peanut protein. A study from the UK reported similarly 62% of their
patients passing the end-challenge. 186 When comparing the success rates of
peanut oral immunotherapy, one must take into account differences in the
published studies, thus inclusion criteria and protocols vary. In addition,
published studies are based mostly on small patient populations, i.e. under 50
OIT patients. In the study by Varshney et al. in the USA, up to 84% (16/19)
patients passed the end-challenge, but one patient was reported to experience
mild symptoms and receive antihistamine. 197 A Japanese study reported 16/18
(89%) patients achieving the maintenance dose (3.5-7g of whole peanut), but no
end-challenges were conducted. 191 The rate of 89% is in line with our 87%
with a very similar goal dose, four peanuts, which corresponds to
approximately 3.2 g whole peanut.
Our secondary outcome in the study of peanut oral immunotherapy was the
effect of the treatment on airways. Airway effects had not been studied during
peanut oral immunotherapy before our study. Many peanut-allergic patients
have asthma, as did the major proportion (69%) of our patients. None of our
patients was excluded from the study due to poor asthma control. One patient
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was diagnosed with asthma based on the baseline airway studies, but this
patient received asthma treatment and was able to start immunotherapy.
Uncontrolled asthma is a risk factor for fatal and near-fatal anaphylactic
reactions in food allergies. 30 We studied the airways through two methods:
Fractional exhaled nitric oxide, to show airway inflammation, and a
methacholine bronchial challenge, to show bronchial hyperreactivity. In
addition, we compared baseline spirometry results. We found no difference in
airway measurements before and after the treatment, which indicates that with
good asthma control throughout treatment, peanut oral immunotherapy does not
cause bronchial hyperreactivity or airway inflammation.
Most of our patients (77%) reported some adverse effects during the eight-
month build-up phase, which is similar to a bigger pooled study on children in
peanut OIT that reported 80% of the study children experiencing side effects.
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No off-treatment period was conducted in our patients. In the published studies,
off-treatment period results in a failure of desensitization in many patients,
213,199 so in this regard any discontinuation of the treatment for research
purposes may therefore not be justified as a routine approach.
Food allergy-related quality of life improved in our patients. In an Israeli study,
patients with the worst quality of life improved during the food immunotherapy
build-up phase, while those patients with better quality of life at baseline even
decreased their quality of life. 255 In our study, parents of the study children
showed no change in the quality of life score. We must take into account that
parents filled in the quality of life questionnaires at the clinic, and patients in
many cases were accompanied by different parent on different visits.
We monitored specific IgE levels and found no statistically significant change
after the build-up phase; in some patients, IgE decreased and in some it even
increased. The duration of the build-up phase was eight months in our study
protocol, and IgE levels may still increase in this phase until they start to
decrease. 189, 191 Immunotherapy patients are immunologically a heterogeneous
group, as the course of their treatment provides patient-to-patient variations
according to success in escalating the dose. In one-year samples, we found a
decrease in IgE levels. In contrast to IgE, the specific IgG4 levels increased
strongly already after the build-up phase, which is in accordance with previous
studies. 189, 191, 224
6.2.2.2 Changes in sensitization profiles during peanut OIT
The microarray screening of IgE levels before and after the peanut OIT
build-up phase showed that desensitization in peanut oral immunotherapy was
highly allergen-specific. Specific IgE only to the major peanut allergens Ara h 2
and Ara h 6 decreased, but no effect was present on specific IgE to other nut
seed storage proteins or on specific IgE to the peanut cross-reactive allergens,
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the PR-10, LTP, and profilin families.
Peanut OIT had the strongest effect on the best markers of severe peanut
allergy, i.e. Ara h 6 and Ara h 2. 109, 256 These 2S albumin allergens share 59%
amino acid sequence identity and are highly cross-reactive. 115 The baseline
specific IgE concentrations of Ara h 1 and Ara h 3 were lower, and the decrease
after OIT failed to reach statistical significance. Our data showed also the
dominance of a serological response to Ara h 2 over Ara h 1 and Ara h 3, which
has been observed in some previous studies of peanut OIT. 191, 199
At baseline, sensitization to 2S albumins–other than peanut Ara h 2 and Ara h
6– was infrequent. Furthermore, peanut OIT had no effect on the low baseline
specific IgE levels, and no novel sensitization to these 2S albumins occurred,
either, which is in line with the fact that cross-reactivity is uncommon in the
2S albumin family. 257 Specific IgE to the hazelnut and cashew 2S albumins
was not affected by peanut OIT, which highlights the fact that peanut OIT
modifies only peanut allergy despite concurrent allergy to other nuts. 258
Our population was highly sensitized to PR-10 proteins. We included patients
with moderate-to-severe peanut allergy, so patients were sensitized to the major
peanut allergens in addition to the common co-sensitization to the minor
allergen Ara h 8, which is associated with mild symptoms. Despite exposure to
Ara h 8 in peanut flour and fresh whole peanuts, our patients exhibited no
changes in the levels of IgE to Ara h 8, Bet v 1, or other PR-10 proteins. This
might be due to the fact that Ara h 8 is degraded in the gastrointestinal tract, or
because of the low content of Ara h 8 in the consumed products. Therefore, oral
immunotherapy may be ineffective for IgE responses to Ara h 8. In contrast, in
subcutaneous birch pollen immunotherapy, IgE to cross-reactive PR-10 proteins
Aln g 1, Mal d 1, Cor a 1.0401, and Pru p 1 decreased. 155
Ara h 9 sensitization was rare in our population, which is in line with previous
studies from Northern Europe. 82 Sensitizations to other LTPs were also
uncommon (5–17%) and mostly of a low level. OIT did not cause novel
sensitizations for Ara h 9 or other LTPs. Ara h 9 content is low in peanut, 80 thus
leading to the lack of an effect on Ara h 9-specific IgE.
We observed that peanut OIT increased the ratio of IgG4 to IgE antibodies for
peanut-specific storage proteins Ara h 1, 2, 3, 6, and the whole peanut extract.
Allergen-specific IgG4 antibodies emerge in the development of natural
tolerance and during specific immunotherapy, 14, 191 and in sensitized
individuals, a high peanut-specific IgG4-to-IgE ratio predicts tolerance. 147, 148
In line with our study findings, with OIT, the ratio of peanut- specific
IgG4-to-IgE can rise from ten- to even a thousand-fold. 227, 148 In our study, the
ratios for Ara h 6 and Ara h 2 increased most and exceeded the rise for whole
peanut, Ara h 1, and Ara h 3. The low baseline rate of sensitization to Ara h 9
might explain why peanut OIT had no effect on the Ara h 9-specific
IgG4-to-IgE ratio in our study. It has been argued that pretreatment IgE
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response to a specific allergen may be needed for the induction of IgG4
antibodies.154 However, the IgG4-to-IgE ratio for Ara h 8 remained unchanged,
even though the majority of our patients were sensitized to Ara h 8 at baseline.
The increase in IgG4 is in accordance with previous reports of decreasing IgE
levels in ISAC, as IgG4 antibodies block IgE binding to the microarray. 149 The
ISAC microarray has been even proposed to work as a tool to monitor the
development of desensitization in immunotherapies to birch and timothy grass
pollens, 155, 154 and it could similarly benefit peanut OIT as a monitoring tool.
As a clinical finding, we observed that the cumulative dose of peanut protein
ingested during OIT was associated with the increase in the specific IgG4-to-
IgE ratio. In patients with a  higher cumulative allergen dose, increases in the
IgG4-to-IgE ratios to whole peanut extract, Ara h 6, Ara h 2, and Ara h 3 were
higher. A specific IgG4-to-IgE ratio might function as a proxy for success in
OIT, as a higher IgG4-to-IgE ratio to peanut is associated with sustained
unresponsiveness. 199
All of our patients had a moderate-to-severe peanut allergy and were sensitized
to Ara h 2 and/or Ara h 6. In addition, the majority of the patients were also
sensitized to Ara h 1 and/or Ara h 3, which indicates a more severe peanut
allergy. 109 We were also able to analyze the change in IgE in relation to a broad
spectrum of peanut-specific and cross-reactive allergens. Dividing the patient
population into subgroups according to OIT success was not possible, though,





Sensitization to birch pollen has a remarkable effect on sensitization to nut
species, and the effect is strong both in southern and northern Finland. Our
study results are generalizable outside Finland, for example Central Europe,
which has less birch pollen than Helsinki region. The most strongly birch-cross-
reactive species are hazelnut, almond, and peanut. Cashew and pistachio, and
walnut and pecan cross-react the strongest. Despite the common finding of
sensitization, many individuals with positive skin prick tests experience only
mild symptoms restricted to the oral cavity. Knowledge of cross-reactivities
allows more detailed patient advice, although further studies with food
challenges are necessary. Our results imply that patients sensitized to some nuts
may be able to receive more specific directions about which nuts can be
consumed safely and which should be avoided. It would be possible to study
cross-reactions in a smaller study population with in vitro studies, component-
specific tests, and severity-graded nut challenges.
Many peanut-sensitized patients can reintroduce several other nut species into
their diet, as species-specific sensitizations to other nut species are infrequent.
However, care must be taken when consuming nuts, as species identification
may be difficult, and in very sensitive patients even contamination may cause
symptoms.
In diagnosing peanut allergy with the ISAC microarray, Ara h 2 and Ara h 6 are
the best allergens. We do not recommend Ara h 8 for diagnosing peanut allergy.
The levels of IgE to peanut seed storage proteins correlate with the challenge
threshold dose. Use of this finding for an individual patient needs further
assessment. A future study on the clinical relevance of the ISAC microarray for
discriminating nut allergies other than peanut, e.g. Brazil nut, cashew, walnut,
and sesame seed allergies, would be of interest and should include double-blind
placebo-controlled nut challenges.
Oral immunotherapy is effective in desensitizing peanut-allergic children and
adolescents. However, not all patients are able to increase the allergen dose and
achieve desensitization. Severe reactions are possible even after longer periods
of treatment, and so warning signs should be considered seriously. Further
studies are needed to assess which patients benefit from the treatment the most.
If particular attention is paid to asthma control, OIT does not have a harmful
effect on bronchial hyperreactivity or airway inflammation. Larger studies are
needed to confirm our results on airway inflammation and bronchial
hyperreactivity. Long-term tolerance and safety, as well as any effects on
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quality of life, should be assessed in longstanding studies. In addition, the
efficacy of oral immunotherapy to peanut should be studied in different age
groups and patients with very high risk of anaphylaxis. In future studies, quality
of life in food allergy immunotherapy would be of great interest, as quality of
life is an important factor in the overall benefits of a treatment. The treatment’s
effect on patients and families as a whole should be taken into account, and it is
important to examine how life quality progresses in the longer term when the
treatment continues or is discontinued due to a lack of motivation, or due to
side effects.
No novel sensitizations emerge or previous sensitizations strengthen during oral
peanut immunotherapy using a natural immunotherapy preparation. The
treatment affects only the most important peanut seed storage proteins Ara h 2
and Ara h 6. The ratio of IgG4 to IgE to seed storage proteins increases during
immunotherapy, and this increase is associated with the ingested cumulative
peanut dose. The IgG4-to-IgE ratio might even serve as a measure for assessing
the progress of immunotherapy. A larger study would offer more sensitivity for
observing small changes in the sensitization profiles in IgE microarrays.
Finally, validating specific IgG4-to-IgE ratio for the assessment of
desensitization in OIT would require larger studies.
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